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Shakespeare formulated in Hamlet: “Thou know’st ‘tis common; all that lives must die”. Aging is one 
of the most universal aspects of life, a process that marks the end of all living organisms, but 
scientifically it remains an elusive process. As humans become older in our society, we are 
more and more faced with the aspects of aging problems. As we improve our understanding 
of aging it has become evident that aging already starts at young age. The accumulation of 
cellular damage already starts at an early age, and influences the process of aging for the 
long run. Cellular aging is also known as cellular senescence, a term derived from the Latin 
word senex that stands for old man or aged. This chapter discusses cellular senescence and the 
changes that occur at different levels during the development of senescence and aging.
Cellular aging 
In 1881, August Weismann already suggested that death takes place because of worn-
out tissue and that tissue cannot renew itself forever.1, 2 In the 20th century this perspective 
on cellular aging was largely forgotten and the general assumption, which was strongly 
influenced by the work of the Nobel-prize winner Francis Carrel, was that all cells can 
divide indefinitely and that mortality in cell culture was a result of sub-optimal culture 
conditions.3 In 1961, this dogma was overturned by the work of Leonard Hayflick and 
Paul Moorhead.4 They showed that primary cells do stop dividing unrelated to cell culture 
conditions by an ingenious but simple experiment, they mixed young female and old male 
cells and after sub-culturing they showed that only female cells were present in the culture, 
providing evidence that the male cells could not have died because of culture conditions.4 
In their article, they describe different phases that can be distinguished during primary 
cell culture. The first phase is the primary culture phase, which is followed by a phase of 
constant growth and cell division. Eventually, cells reach as they described it “the phase 
III phenomenon” in which cell replication diminishes and eventually stops. This phase III 
became later known as “the Hayflick limit” or cellular senescence. The non-dividing cells 
remained viable for many weeks, but failed to grow despite the presence of growth factors 
and ample space.
The importance of cellular senescence in relation to aging of organisms became clear 
when it was shown that donor age of an organism influenced the proliferative capacity 
of cells.5, 6 From the work of Hayflick and others it became clear that there might be an 
internal clock in all cells that determines mortality and aging.7 It was in 1973 that the link 
between telomeres and the end-replication problem was suggested.8, 9 The end-replication 
problem describes the predicament that during DNA replication the lacking strand of 
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the DNA cannot be completely replicated and therefore shortens at each mitotic cycle. 
A few years after the discovery of telomeres10, and the enzyme telomerase11 the importance 
of chromosomal ends in relation to the onset of senescence became clear.12, 13 The role 
of telomere shortening and the role of the enzyme telomerase in aging are discussed in 
chapter 2 of this thesis.
Nowadays, we make a global distinction between two types of cellular senescence, both 
result in a comparable non-dividing end-point, but there is a difference on how senescence 
is originating. The non-dividing phase described by Hayflick where cells reach senescence 
after a number of population doublings is called replicative senescence. Not only old cells can 
become senescent, also relatively young cells can obtain a senescent phenotype. According 
to Harman’s free radical theory of aging, in which he suggested that oxidative stress in the 
form of reactive oxygen species (ROS) and other redox reactions could negatively influence 
aging. This second form of senescence can be induced by different forms of cellular stress, 
such as UV or radioactive radiation14, or oxidative stress15, or exposure to increased levels of 
glucose.16 17 The general accepted hypothesis for the onset of premature senescence is that, 
after sub-lethal doses of stress, a cell signaling cascade is activated that eventually results 
in a premature interphase G0 arrest – this process is termed stress induced premature 
senescence.
Morphological and molecular changes in senescence
Senescent cells undergo a very characteristic set of morphological changes that is easily 
recognizable in cell culture. As mentioned before senescent cells become arrested and can 
maintain this state in culture for a long period of time. In cell culture, senescent cells are 
relatively easy to recognize. The most obvious change is the increase of cell size, which is 
accompanied with a change in cytoskeletal proteins as actin, tubulin and vimentin.18, 19 
The cytoplasm becomes highly vacuolated and the nucleus is located centrally in senescent 
cells and in some senescent cells multi-nucleation occurs.
In vivo, senescent cells are not that easily recognizable. Senescence does not occur in 
cells that have lost the ability to proliferate, such as differentiated cardiac muscle and 
neuronal cells, but can originate in mitotic cells that have the potential to proliferate. As 
many cells in somatic tissue are in a quiescent state and hence do not divide for weeks to 
months, distinguishing senescent arrested cells from quiescent cells is difficult. However, 
also at the biochemical level changes occur in senescent cells and the increase of lysosomal 
β-galactosidase has been of great importance in senescence research.20, 21 Dimri et al. 
described in 1995 that detection of β-galactosidase at a pH of 6 could be used as a marker 
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for senescence in vitro and in vivo20, and this staining is now widely used and has been 
termed senescence associated β-galactosidase (sa-β-gal) staining (Figure 1). Since then, 
there has been a lot of discussion on the relation of β-gal to cellular senescence and about 
the specificity of sa-β-gal.22, 21, 23, 24 It was discovered that lysosomal β-gal is a side effect of 
aging and does not influence the onset of senescence.24  We now know that sa-β-gal can be 
detected by sensitive HPLC methods in young and old cells22, and also that serum deprived 
cells or cells that have reached confluence can stain positive for sa-β-gal.23 Therefore, 
many researchers use multiple markers aside the sa-β-gal staining to establish senescence. 
Nevertheless, sa-β-gal staining remains the most used technique, since it can be easily 
conducted and is still accepted as a cellular marker for senescence in vivo and in vitro. 
On the molecular level, there are two major pathways involved in the induction of 
senescence. Replicative, telomere dependent senescence and DNA damage induced 
senescence is associated with DNA damage signaling by ATM / ATR kinases that subsequently 
activates the tumor suppressor protein p53, which regulates the cyclin-dependent kinase 
inhibitor p21.25 The second pathway is dependent on the activation p38MAPK followed by 
the activation of the cyclin-depend kinase inhibitor p16.26 Activation of p38MAPK occurs 
after activation of the senescence by oxidative stress, and is also involved in protooncogene, 
induced senescence.27 Interestingly, p38MAPK induced senescence can be telomere-dependent 
and telomere-independent.26  There is also overlap with DNA damage induced senescence, as 
p53 can also become activated after p38MAPK induced senescence.28 Activation of P38MAPK can 
increase intra-cellular levels of oxidative stress that results in p53 and p21 activation.15, 29 
Both pathways eventually converge at the cell cycle regulator retinoblastoma protein (Rb) 
that in its hypophosphorylated active state inhibits progression to S-phase of the cell cycle 
(Figure 2). Although these pathways can induce senescence independently, there is overlap 
Figure 1. Senescent endothelial cells. 
Senescent HUVECs and neighboring 
non-senescent cells. Senescent cells stain 
positive for sa-β-gal, are larger, and can 
display an abnormal nuclear structure. 
Arrows indicate sa-β-gal positive cells.
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between the pathways. The importance of a route can differ between cells and species. For 
instance, in human cells pRb can be activated independent of p53, through the upregulation 
of p16, while in mouse cells upregulation of p16 does not induce senescence.30
Cellular senescence and apoptosis
Senescence and apoptosis share common elements, both processes are a response to 
cellular stress and mark the end of a cell. But whereas in senescence a cell becomes arrested, 
apoptosis entails the complete destruction and subsequent elimination of stressed cells. 
How cells respond to stress can vary between cells and between cell types. Fibroblasts in the 
S-phase commit to apoptosis after sub-lethal doses of oxidative stress, whereas cells in the 





in fibroblasts, but exposure to higher concentrations results in a apoptotic outcome.32 
Stressors that induce senescence at a sub-lethal concentration can induce apoptosis at higher 
concentrations or prolonged exposure. It is still elusive, what determines the final fate 
Figure 2. Pathways to senescence. Senescence is mediated by different pathways that converge 
on hypophosphorylation of Rb. Different forms of cellular stress can induce senescence either by 
activating p53/p21 or p38/p16 pathways.
14
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of a cell, but it probably depends on certain molecular thresholds. The tumor suppressor 
protein p53 is a critical component in controlling cellular activity. The protein can undergo 
a series of posttranscriptional changes, such as phophorylation and acetylation. In response 
to stress p53 becomes activated by posttranscriptional modifications and activates p21. 
The activation of p21 can result in senescence, but can also induce apoptosis depending 
on the activation of p16.33 The exact mechanisms how p53 determines a cells fate, are still 
undetermined.
The occurrence and function of senescence in aging 
The onset of senescence and the presence of senescent cells in primary cell culture is an 
accepted phenomenon, but it is still unclear what the role of senescence is in aging. Given 
that senescent cells do not proliferate, an anti-cancer mechanism has been suggested for 
this phenomenon.34, 35 This idea is strengthened by the findings that oncogenes such as RAS, 
RAF and PTEN can induce senescence.36, 37, 35 Recent data also suggest that senescence is in vivo 
an important tumor suppressor mechanism, in human and in mouse tissues.38, 37, 39, 40 From 
an evolutionary point of view, a tumor suppressor function is not that peculiar. Selection 
for this trait in reproductive individuals may be beneficial for survival, it is at a later stage 
in life that the presence of senescent cells becomes less advantageous.
Advanced aging is associated with an increase in systemic levels of oxidative stress.41, 42 
In parallel there is a decrease in the antioxidant systems with aging.43, 44 The hypothesis 
that senescence contributes to aging is therefore very tempting, but the concept is still 
under debate.45, 46 With the discovery of more senescent markers, an increasing amount of 
evidence is gathered showing the presence of an increased number of senescent cells in 
aging tissue.20, 47-51 In old baboons more than 15% of the dermal fibroblasts showed signs 
of senescence in the form of damaged telomeres, activated DNA damage response kinase 
ATM and increased levels of p16.49, 50 An overall increase of the aging and DNA damage 
marker gH2AX was found in multiple organs such as the lung, spleen, dermis, liver and 
gut epithelium organs of aging mice.51 In contrast, in these studies senescent markers were 
not detected in all organs, post mitotic tissue, such as skeletal and heart muscle was less 
affected by age.50, 51 Increased levels of the senescence marker p16 were detected in human 
kidneys in relation to aging.48 In diseased renal transplants, this marker was also increased 
suggesting that the presence of senescent cells in the diseased kidney and aging may share 
common pathways.52 In line with this is the finding that senescence is also increased in the 
kidneys of patients with type II nephropathy.53 
At the moment, it is unclear what happens to senescent cells in the body. There are 
differences in the susceptibility to apoptosis between different cell types. Senescent 
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fibroblasts are described to become less sensitive for apoptotic signaling54, while aged 
endothelial cells seem to become more sensitive to apoptotic stimuli.55 Another part of 
senescent biology that is still emerging, is the response of the immune system to senescent 
cells. In fibroblasts and endothelial cells, senescence is characterized by the upregulation of 
a gene pattern that is comparable to genes that are upregulated during inflammation. This 
is accompanied by an increase in inflammatory surface markers and cytokines.56-58 These 
changes could possibly provoke clearance of these cells by the innate immune system59, 
but this still needs proper conformation in different aging models, and further testing in 
human studies.
Vascular senescence
For vascular disease, advanced age is one of the major risk factors, even a higher risk 
than smoking, hypertension, diabetes or hypercholesterolemia.60 As the vasculature is at 
the boundary of blood circulation and the underlying tissue, the vasculature is constantly 
exposed to a variety of stresses, such as hemodynamic stress, and oxidative stress in the 
form of reactive nitrogen species, ROS and different forms of oxidized lipids.61, 62 The 
constant exposure to stress gives rise to the development of endothelial dysfunction, 
a pro-inflammatory state of the vasculature, in which the balance of vasoconstriction 
and vasodilatation is disrupted.63 The occurrence of endothelial dysfunction is a hallmark 
of cardiovascular disease and occurs in patients with diabetes mellitus, hypertension, 
hypercholesterolemia, atherosclerosis and heart failure.63 Therefore, improving endothelial 
function has the potential to decrease the risk for progression of cardiovascular disease and 
could potentially improve the quality of life of a large group of patients. 
The occurrence of senescent cells in the vasculature has been most striking in atherosclerotic 
patients. Coronary artery explants, from ischemic heart disease patients, showed that the 
luminal surface of the vessel stained almost completely positive for sa-ß-gal, while internal 
mammary arteries of the patients were completely negative.64 Histological examination of the 
positive vessels showed that it where predominantly endothelial cells that stained positive. In 
advanced atherosclerotic plaques senescent positive vascular smooth cells were also detected 
in the intima regions.65 As senescent endothelial cells are more prone for apoptosis, this could 
in vivo result in denuded patches within the vasculature, exposing smooth muscle cells to the 
circulation and increase the incidence of atherosclerosis and thrombosis.66 
Angiotensin II (Ang II) signaling is an important component of vascular stability and 
vascular function and seems to have an important influence on vascular aging as inhibition 
of Ang II can improve morbidity and mortality of cardiovascular disease.67 Ang II can 
induce senescence in vascular smooth muscle cells via a p53/p21 dependent pathway that 
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is independent of telomere shortening68, 69 and inhibition of the pathway can suppress 
senescence. Interestingly, loss of p21 ameliorates the induction of pro-inflammatory 
molecules by Ang II and prevents the development of atherosclerosis.68, 70 Although the 
inactivation of p21 also influences the pro-inflammatory state and phagocytic activity of the 
macrophages, it is likely that the state of the macrophages also influences the development 
of atherosclerosis in these models.70 
Endothelial senescence can be induced by diabetes mellitus, as has been shown in 
an animal model with streptozotocin, a broad spectrum antibiotic that has diabetogenic 
properties71, in mice and rats.16, 72 Senescent positive cells have also been detected in the 
aorta of Zucker diabetic fatty (ZDF) rats, an animal model that is used for studying diabetes 
mellitus and a model that develops endothelial dysfunction.16, 73 Histological analysis 
showed an increase in cells staining positive for the senescent associated proteins p53, p21 
and p16 in the vasculature of ZDF animals.73 
Oxidative stress is a common denominator for the development of endothelial 
dysfunction.61, 62 The vasculature can produce different forms of ROS, superoxide (O
2
-•), 




), and peroxynitrite 
(ONOO-•), under normal and under stress conditions, such as inflammation or injury. ROS 
is produced by different enzymes, such as NADH oxidase, xanthine oxidase, cyclooxygenase, 
NO syntase (NOS), cytochrome P450 monooxygenase and by enzymes involved in the 
mitochondrial respiratory chain. Superoxide is relatively unstable and reacts (direct or by 








 is converted to water 
and oxygen
 
by catalase or gluthione peroxidase, during this reaction the highly active 
hydroxyl radical can be formed, which causes cellular and DNA damage.74 The generation 
of ROS is essential for the regulation of cellular processes, and also influences vascular 
dilatation and constriction. Where an excess of ROS tips the balance to vasoconstriction, as 
ROS inhibits the three predominant vasodilator pathways; NO, prostacyclins and endothelial 
derived endothelium-derived hyperpolarizing factor (EDHF).63 In the aging vasculature, 
the production of exo- and endogenous ROS increases, which negatively influences 
vasodilatation. NO is a crucial mediator of vasodilatation, and an excess of superoxide 
reduces the bioavailability of NO by generating the highly damaging agent peroxynitrite.63 
In addition, there is evidence that persisting oxidative stress will render the enzyme responsible 
for the generation of NO, endothelial NOS (eNOS), dysfunctional, such that it produces 
superoxide instead of NO.75 Another factor that negatively influences the NO bioavailability 
is the down-regulation of eNOS in senescent cells.64 Interestingly, inflammation plays a key 
role in the atherosclerosis and is suspected to be an important precursor of endothelial 
dysfunction.63, 76  The onset of senescence coincides with the upregulation of inflammatory 
genes and proteins like ICAM-1, IL-6 and IL-8, which could intensify the pro-inflammatory 
state of the vasculature that is so conspicuous for endothelial dysfunction.57 
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The scope of this thesis
This thesis will discuss the effects of cellular aging, and the main focus will be at 
telomere biology and senescence in cardiovascular diseases. The first part of the thesis will 
discuss the effects of telomere shortening and the role of telomerase in aging associated 
diseases, with a focus on cardiovascular diseases. The main question discussed in this part is 
how does telomere length and telomerase deficiency influence cardiovascular aging. 
Part II of the thesis will focus on the effects of stress induced cellular senescence on 
endothelial cells, in this part we will show how the activation of G-protein coupled receptors 
by specific hormones can activate cellular pathways that protect endothelial cells from 
oxidative stress induced senescence. The main question described in Part II is twofold: Is it 
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Aging is a biological process that affects most cells, organisms and species. Telomeres 
have been postulated as a universal biological clock that shortens in parallel with aging in 
cells. Telomeres are located at the end of the chromosomes and consist of an evolutionary 
conserved repetitive nucleotide sequence ranging in length from a few hundred base 
pairs in yeast till several kilo base pairs in vertebrates. Telomeres associate with shelterin 
proteins and form a complex protecting the chromosomal deoxyribonucleic acid (DNA) 
from recognition by the DNA damage-repair system. Due to the “end-replication problem” 
telomeres shorten with each mitotic cycle resulting in cumulative telomere attrition during 
aging. When telomeres reach a critical length the cell will not further undergo cell divisions 
and become senescent or otherwise dysfunctional. Telomere shortening has not only been 
linked to aging but also to several age associated diseases, including tumorigenesis, coronary 
artery disease, and heart failure. In the current review, we will discuss the role of telomere 
biology in relation to aging and aging associated diseases.
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“Death takes place because a worn-out tissue cannot forever renew itself, and because a capacity for increase by means of cell 
division is not everlasting but finite”
A. Weismann. Clarendon, Oxford 1881
A brief historical perspective
Telomeres are special deoxyribonucleic acid (DNA) structures that “cap” the ends of our 
chromosomes in conjunction with specialized proteins, the telomere-shelterin complex. 
This complex protects the chromosomes from erosion and end-to-end fusion. The term 
telomere originates from the Greek telos, which means “end” and meros which means 
“part”. The existence of these end-parts of the chromosomes was first suggested in 1938 
by Muller.1 In 1961, Hayflick undermined a major paradigm of his time by providing 
convincing evidence that primary cells were not immortal, but could undergo only a limited 
number of cell divisions. This phenomenon, currently being referred to as the Hayflick 
limit2, predicts the existence of an internal counting mechanism within the cell. Olovnikov, 
a Russian researcher, was the first who linked the end of the chromosomes to the cell cycle 
arrest described by Leonard Hayflick.3 The term “end-replication problem” describes the 
effect that linear chromosomes cannot replicate their terminal ends of the chromosome 
and consequently shorten at each mitotic cycle. The first identification of the sequence of 
the terminal end of the chromosome (the telomere) in the Tetrahymena was discovered by 
Elizabeth Blackburn and Joseph Gal in 1978.4 Ten years later, Robert Moyazis and colleagues 
revealed that the sequence of the human telomere consists of TTAGGG repeats.5 Up to date, 
the sequence of many species and organisms have been established and we can conclude 
that the telomeres are an evolutionary well-conserved sequence (Table 1).6 The next major 
breakthrough in telomere biology was the discovery of the reverse transcriptase telomerase 
by Carol Greider working as a postdoctoral student at the laboratory of Elizabeth Blackburn 
in 1985.7 In contrast to DNA-polymerase, telomerase is capable of elongating the telomeres. 
Bypassing the end-replication problem for germ cells is essential to maintain telomere 
length for offspring. In 1997 Maria Blasco in the lab of Carol Greider created a telomerase 
deficient mouse, which had inactive telomerase and consequently reduced telomere length 
in each following generation.8 The most striking characteristic of the telomeres in somatic 
cells is the shortening with age and in cell culture the telomere length is directly linked to 
the replicative capacity. In this review, we will discuss the function of the telomeres and will 
focus on the importance of telomere biology in normal aging and in pathology.
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Telomere; structure and T-loop
In vertebrates, the end of the chromosome, a G-rich strand, ends in a single strand 
extension of 75–200 bp, the G-tail (Figure 1). In the nonmitotic phase of the cell cycle 
this G-tail is shielded by a crucial so-called telomere shelterin complex in which the 
telomere binds internally by forming two internal loops, the D-loop and the T-loop.9 The 
telomere shelterin complex is designed to protect the chromosomal ends from erosion and 
end-to-end fusion10 and is formed by different proteins associated with the telomeres, such 
as telomeric repeat binding factor 1 (TRF1) and 2 (TRF2) that can bind to double stranded 
telomere DNA. Another telomere associated protein, protein protection of telomeres 1 
(POT1), can bind directly to single stranded DNA, and it is suggested that POT1 binding to 
the 3’overhang is important for forming the D-loop. Other proteins involved in the shelterin 
complex that are recruited by TRF1 and TRF2 are repressor activator protein 1 (Rap1), TPP1, 
and TRF1-interacting nuclear factor 2 (TIN2) (Figure 2).10 Telomere shortening will result 
in destabilization of the chromosomes and an inability to recruit the proteins of the shelterin 
complex. As a result, the T-loop cannot be formed as easily and the chromosome ends 
will be left uncapped. This is a situation that resembles double stranded DNA breaks, and 
presents a highly unstable cellular state that may lead to activation of the p53 or p16ink4a 
pathway and eventually can result in senescence or apoptosis.11
Table 1. Telomere length and telomere sequence in different species.
Species Telomere length Telomere sequence Reference
Ciliates 
Protozoan  




(S. cerevisiae) 200 - 300 bp TG2-3(TG)1-6
120
Vertebrates
Humans 5 -15 kb T2AG3
5
Mice Up to 150 kb T2AG3
21
Rats 20 -100 kb T2AG3
22
Birds 5 – 20 kb T2AG3
23
Invertebrate




(A. thaliana) 2 – 5 kb T3AG3
122
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Telomere length and aging
In contrast to the similarity of the sequence, the telomere length is highly variable 
among species, within species, within an organism, and even between chromosomes. In 
a study that evaluated telomere length in different organs from humans of different age, 
telomere length varied between 8 and 15 kbp and was highly variable between organs from 
one subject.12  This may be explained by variable telomere attrition rate, in humans it is 
estimated that telomere length shortens 30–150 bp per replication cycle in fibroblasts and 
lymphocytes.13, 14 There is a high amount of variance in telomere length in humans. Already 
at birth, remarkable differences in telomere length are observed. In addition, females have 
longer telomeres than men and in African Americans telomeres generally are longer than 
in White Americans.15 As there is no gender difference at birth, it is most likely due to 
differences in environmental factors such as differences in estrogens levels.16 Strikingly, 
macaques have approximately the same life span as humans but have longer telomeres in 
addition to a longer subtelomeric region.17 Telomere attrition rate is not stable for each 
chromosome, in human cells the chromosomes 17p, 13p, and 19p have been identified as 
being shorter compared to the other chromosomes.18, 19
In humans, telomere length is measured extensively in leukocytes in relation to aging 
and various pathologies. Leukocyte telomere length obviously has the advantage of being 
Figure 1. Telomeres are located 
at the very final ends of the linear 
chromosomes and consists of TTAGGG 




relatively easily obtained and processing is a relatively simple process. Telomere length in 
leukocytes is highly variable among individuals and decreases throughout life. Especially 
large differences develop the first few years after birth20 after which telomere length are 
relatively stable throughout childhood, preadolescent, and adolescent years. Eventually, te-
lomere length attrition increases at very old age (Figure 3). An important aging hypothesis 
is that telomere attrition increases at the onset of disease. Therefore, telomere length of the 
leukocytes could be a good marker for disease. Telomere length in different aging diseases is 
discussed later in the review. The major disadvantage of using leukocyte telomere length is 
that it is a measure of the activity state of the immune system and one might argue that leu-
kocyte telomere length is rather a representation of increased inflammation than of aging.
Most animal research on telomeres has been performed in rodents, especially on 
inbred mice and rat species that have highly variable telomere lengths. Laboratory rats have 
relatively long telomeres that vary between 20 and 100 kb and telomere length in mice is 
even more variable and can extend up to 150 kb (of the C57BL/6 mice).21, 22 In contrast, 
the outbred (wild type) mice strain Mus spretus has telomere length that is comparable to 
human cells. Comparing multiple mice strains showed that most mouse species do not have 
long telomeres, and long telomeres in mice strains originate from excessive breeding.21 In 
rats, telomere length shortens with aging in several organs like kidney, liver, pancreas, and 
lungs. Research into telomere length from blood derived cells from multiple bird species 
with different life expectancies shows that telomere attrition rate is a better predictor of life 
expectancy than the age of the animal.23 One remarkable animal is the Leach’s storm-petrel, 
a long lived bird species with a maximum observed lifespan of 36 years. Instead of telomere 
attrition, it is suggested that the telomere length increases during aging in this species.23 
The Leach’s storm-petrel has increased levels of telomerase activity in their bone marrow 
cells compared to other birds.24 It is tempting to speculate that these animals have managed 
Figure 2. Schematic 
representation of the telomere 
shelterin complex and its 
associated proteins; TRF1, TRF2, 
POT1, Rap1, TIN2, and TPP1.
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to increase their lifespan by dealing with telomere erosion. However, the assumption that 
absolute telomere length has an effect on life span is still elusive. For example, mice strains 
with longer telomeres do not seem to have an increased lifespan compared to mice strains 
with shorter telomeres. How these differences in telomere length affect lifespan are still 
unknown, the most accepted hypothesis is that the shortest telomeres are contributing 
most to the expected lifespan.25
Telomere biology and cellular senescence
Primary cells in culture are not immortal. As Hayflick demonstrated in 1961, cells stop 
dividing after a certain number of passages and become sedative2, a phenotype also known as 
replicative senescence. The senescent phenotype is accompanied by changes in morphology, 
gene expression, and proteins. Beta galactosidase staining is frequently used to identify 
senescent cells and is associated with changes in p53, p16, and p21 expression.26-28 There 
are multiple stimuli that can induce senescence; telomere shortening, DNA damage, and 
induction of oncogenic or tumor suppressor signals.29-31 Induction of cellular senescence 
is an important suppressor of tumorigenesis.30, 32 Although telomere attrition might not 
be primarily involved in the acute induction of senescence29, the cumulative burden 
of oxidative stress and the cumulative telomere attrition might increase to likelihood 
of a cell to enter senescence.31 Telomere attrition through replication and accumulation 
of DNA damage can result in an increase of senescent cells in different tissues and organs 
eventually resulting in decreased function and pathology. Telomere shortening has been 
implicated as one of the major mechanisms of replicative senescence.14  The end-replication 
problem accounts for a loss of ~100 bp telomere length at each population doubling. On 
Figure 3. Telomere length in 
lymphocytes and granulocytes during 




average cells are estimated to reach senescence after ~50 population doublings. This is a bit 
earlier than predicted by the end-replication problem alone. It is likely that the state of the 
telomere and the presence of the proteins involved in forming the shelterin complex are 
important cofactors associated with the induction of senescence.33 For example, there is 
ample evidence that disruption of the telomere binding proteins results in early senescence. 
In primary human fibroblasts, TRF2 inhibition induces a p53- and retinoblastoma-
dependent senescent phenotype.33, 34 Likewise, inhibiting POT1 by RNA interference led 
to the disappearance of the telomeres single-stranded overhangs and induced apoptosis, 
chromosomal instability, and senescence.35
Telomere biology in stem cells
Stem cells and progenitor cells have an important role in maintaining tissue homeostasis 
by replenishing (senescent, apoptotic) cells and repairing damage that occurs throughout 
life. Exhaustion of the stem cell or progenitor cell pool has been considered an important 
factor in the aging process of an organism.36 One of the hallmarks of stem cells is their 
telomerase activity and stable length of their telomeres.37, 38 Stem cells reside in different 
compartments throughout the body. In mice it has been shown that there exists a large 
difference in telomere length among the different compartments. The longest telomeres have 
been observed in skin, small intestine, cornea, testis, and brain compartments.39 Although it 
seems that stem cells have stable telomeres by its increased telomerase activity, it does not make 
them invulnerable to telomere erosion. Clonal expansion after damage or in a disease state 
could induce telomere erosion that ultimately could induce senescence and an exhaustion 
of the stem cell pool. This hypothesis is supported by data from bone marrow-derived cells 
exhibiting a decreased migratory capacity and significant telomere shortening in patients 
with coronary artery disease.40 The best characterized stem cells are the hematopoietic stem 
cells (HSC) which continuously replenish the hematopoietic cell lineages. HSC have been 
reported to have shorter telomeres compared to fetal liver and cord blood derived cells.41 
Recent data have also suggested a reduction of telomere length of HSC during aging.42
Telomere biology and premature aging
Some human disorders associated with shorter telomere length originate from defective 
telomerase function or mutations in the DNA repair system. For example, Dyskeratosis 
congenita (DC) is a human premature aging syndrome linked to mutations in the telomerase 
complex resulting in decreased telomerase stability and shorter telomeres.43 Patients with 
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DC develop numerous different pathologies, including short stature, hypogonadism, 
infertility, bone marrow failure, skin defects, hematopoietic defects, and premature death. 
In addition, these patients have an increased susceptibility to develop malignancies. Another 
human disease example that involves a telomerase mutation is aplastic anemia. Subjects with 
aplastic anemia experience accelerated telomere shortening and die young.44 Some diseases 
originating from mutations in genes of the DNA repair system also result in a phenotype 
characterized by accelerated telomere shortening and premature aging. Example genes 
include the Ataxia telangiectasia (ATM), Werner syndrome, Bloom syndrome, and Fanconi 
anemia genes. Most of these DNA repair genes also have a role in telomere biology. Mouse 
knockout models for these proteins do not always result in the same characteristics as the 
human disease. It has been suggested that the remarkable longer telomere length in mice 
might provide an explanation for these discrepancies. Combining DNA repair KO mice for 
Werner, Bloom, and ATM syndrome with the TERC-/- mice indeed resulted into a phenotype 
with characteristics that more closely resembled the expected pathology in humans.45
Telomeres and aging associated diseases
The debate on how telomere biology affects life span is ongoing, but a link between 
telomere length and mortality has been established. In addition, numerous associations 
between aging-associated diseases and telomere length have been reported.46 Telomere 
length could be considered as a biological parameter that intertwines replicative history and 
exposure to environmental stress. Human life span is highly dependent on the development 
of aging associated diseases especially cancer and cardiovascular disease.
Cancer
Tumorigenesis is a major factor influencing life expectancy in long-lived species. Shorter 
telomere length is also a risk factor for the development of cancer.47 Progressive shortening 
of the telomeres will lead to activation of the DNA damage response.48, 47 In the normal 
situation this will result in activation of ataxia telangiectasia mutated (ATM) and ataxia 
telangiectasia- and Rad3-related (ATR), and the associated downstream factors including 
CHK1, CHK2, and phosphorylation of p53. In the setting of a competent p53 pathway, 
senescence or apoptosis will be initiated and tumorigenesis inhibited.49 However, when 
the p53 pathway is inadequate tumorigenesis is no longer inhibited in the presence of 
telomere dysfunction.48-50 In addition, 80 to 90% of all tumors express telomerase or have 
a form of alternative telomere lengthening.51 Clinical data revealed that telomere length 
(measured in lymphocytes) is shorter in subjects with different types of cancer, including 




Next to cancer, cardiovascular disease and its risk factors are the major contributors to 
the population’s disease burden during aging. For example, the presence of diabetes has been 
linked to reduced telomere length.52-54 In the Framingham Heart Study, even a subclinical 
presence of insulin resistance was associated with reduced telomere length.55 Hypertension 
and the responsiveness to angiotensin are related to outcome in humans.56, 57 The number 
of genetic variants influencing the development of hypertension is only small.58 However, 
a role for telomeres has been suggested, normotensive persons with short telomeres were 
more susceptible to develop hypertension and hypertensive subjects with short telomeres 
were more susceptible to develop atherosclerosis.59 Interestingly, even subclinical activation 
of the renin-angiotensin system (RAS) has been associated with shorter telomeres.55, 60 
A final example is cigarette smoking, a strong risk factor for the development of coronary 
heart disease.61 Smoking negatively affects telomere length62-64, possibly due to mechanisms 
involving oxidative stress.65
Atherosclerosis
Endothelial dysfunction is recognized as one of the earliest events of atherogenesis66 
and is associated with classical risk factors or risk markers including cholesterol and 
inflammatory markers67, 68, which can be modified by pharmacological treatment.57 
The endothelial and smooth muscle cells in the vessel, which are most susceptible to 
develop atherosclerosis are highly proliferative and are subjected to stress by increasing 
mean arterial pressure, increased cholesterol, and increased oxidative stress. This results 
in an increased susceptibility for senescence.69, 70 Indeed senescent-positive endothelial 
cells can be found in almost any atherosclerotic plaque71 and an association with shorter 
telomeres in atherosclerotic plaques has been established.72 The first clinical study linking 
coronary artery disease to telomere length dates back to 2001.73 This ground breaking 
study suggested telomeres of circulating white blood cells to be approximately 300 
bp shorter in patients with coronary artery disease compared to controls. The authors 
estimated that this telomere differences resembles an age difference of almost 9 years.73 
Further and larger scale studies confirmed these findings and extended it to premature 
atherosclerosis and ischemic heart failure.46, 74-76 For example, the West of Scotland Primary 
Prevention Study (WOSCOPS) observed that subjects in the middle or lower tertile of 
telomere length were at greater risk to experience a clinical manifestation of coronary 
heart disease than persons with longer telomeres.75 The WOSCOPS data also suggested 
that the use of statins was more beneficial for the patients with the shortest telomeres.75 
Apparently patients that are protected by longer telomeres addition of statin treatment 
did not result in additional protection. Interestingly, telomeres of offspring from subjects 
with coronary artery disease already have shorter telomeres compared to offspring from 
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parents without atherosclerosis.77 This might explain part of the heritability of coronary 
artery disease next to other genetic factors.78, 79
Heart failure
Chronic heart failure (CHF) is the main cardiovascular discharge diagnosis in the United 
States.80 In particular, after the necessity of hospital admission, CHF is associated with 
a high mortality rate.81 Recent clinical trials have not added much to the prognosis, and the 
search for new strategies is intensive.82-85 Although in general, the incidence and prevalence 
of CHF steeply increases with aging, there exists a striking variability in the susceptibility, 
age of onset and pace of progression. This variability cannot completely be attributed to the 
presence of conventional risk factors and recent evidence is suggesting a role for telomere 
biology.86 Endomyocardial biopsies from patients with heart failure have demonstrated that 
diseased hearts are characterized by shorter telomeres, increased cellular senescence, and 
cell death.87 It has been estimated that telomere length is reduced by as much as 25% in 
failing hearts compared to nonfailing hearts.88 Also, the telomere length in leukocytes of 
subjects with heart failure are significantly shorter compared to age and gender balanced 
controls.89 In this study, the severity of heart failure symptoms was also associated with 
the degree of telomere shortening. Furthermore, cardiac function as measured by ejection 
fraction in general has been associated with telomere length.90 One standard deviation of 
longer telomere length was associated with a 5% higher left ventricular ejection fraction. In 
these elderly subjects, telomere length alone accounted for 12% in the observed variability 
of ejection fraction. Renal function impairment relates to even worse outcome in patients 
with CHF. Shorter telomere length in CHF is also associated with decreased renal function, 
possibly due to drop-out of functional nephrons.76
Telomere maintenance
Telomerase, a ribonucleoprotein complex that is composed of RNA and protein 
components, can elongate the telomere sequence in mammals and yeast by binding to the 
open end of the G-strand. Telomerase is highly expressed during embryonic development 
but its expression is suppressed within a few weeks after birth in most somatic cells. 
Highly proliferative cells maintain high levels of telomerase, like stem cells, progenitor 
cells, lymphocytes, skin keratinocytes, and cancer cells.91 The major components of the 
active telomerase complex are telomerase reverse transcriptase (TERT), a telomerase RNA 
component (TERC, that is complementary to the telomere sequence) and dyskerin, which 
is a protein that binds to both TERT and TERC and increases stability of the complex.92, 93 
Elongation of the telomeres in mammals and yeast not depending on telomerase is called 
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alternative lengthening of telomeres (ALT). In human tumors, it was discovered that cells 
negative for telomerase could also elongate their telomeres by a recombination mechanism.94 
Recombination takes place by binding of the ALT-associated promyelocytic leukemia bodies 
to the telomeres. Telomere elongation occurs heterozygous in these cells and ALT can best 
be recognized by the presence of both short and long telomeres.
The TERC-/- mouse has increased our knowledge on the importance of telomerase in 
aging and in the potential role of telomerase and telomere shortening in the different 
diseases. As always, it is difficult to translate data from knockout models directly to human 
pathology, but especially in premature aging diseases the TERC-/- mice show great overlap 
with human disease.45 
The telomerase-deficient mice
Telomerase-deficient mouse models
The notion that mouse and human tumors express elevated levels of telomerase activity, 
while normal adjacent tissue lacks measurable activity, led to the development of models 
to study telomere biology. In 1997, Dr Maria A. Blasco reported the successful generation 
of telomerase-deficient mice by knocking out the RNA template of telomerase (TERC-/- 
mice).8 This mouse model was established to serve as a tool to study tumor formation 
and cell viability in the absence of telomerase. Besides the RNA template, another essential 
component of telomerase is the TERT. Not surprisingly, TERT-/- mice have also been 
constructed.
Although originally generated to serve research related to oncology, the telomerase-
deficient mice have provided valuable information for age-associated diseases, including 
those related to cardiovascular disease.
General phenotype of the telomerase-deficient mouse
The telomeres of the TERC-/- mice shorten at a rate of ∼5 kb in every subsequent generation.8 
Therefore, experiments using TERC-/- mice commonly involve several generations (G) of 
these mouse compared with wild types. Telomere length in G3 TERC-/- mice decreases as 
much as 50% during ageing from 1 to 16 months.95 TERC-/- mice of later generations show 
increasingly severe structural abnormalities on cellular level, including undetectable short 
telomeres, aneuploidy, and chromosomal end-to-end fusions.8 In general, animals with 
phenotypical features of ageing have shorter telomeres than age-matched controls from 
the same generation lacking a clear ageing phenotype. Later generations TERC-/- mice show 
a decreasing life span (Table 2). Autopsy of late generation spontaneously diseased animals 
could not identify a clear cause of death, comparable to natural death in humans.95 Later 
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generation and aged TERC-/- mice show many more defects than earlier generation and 
younger TERC-/- mice. These defects include reduced body size and weight, hair graying 
and loss, infertility and testicular atrophy, spleen atrophy, signs of immunosenescence, and 
bone marrow proliferative defects.95, 96  Wound healing is also impaired in aged animals 
TERC-/-.95 Reduced angiogenic potential of these mice has been suggested as an explanation 
for this observation. Below we will focus in more detail on the knowledge of the angiogenic 
potential in these mice.
Although some interesting studies have been performed on TERT-/- mice, these mice are 
substantially less well-studied compared with TERC-/- mice. The construction of the TERT-/- 
mice has first been reported in 1999.97 Both the TERT-/- and the TERC-/- mice do not show 
significant phenotypic abnormalities at early age in the first generation. Unfortunately, 
information on the general phenotype of the TERT-/- mice of later generations is sparse and data 
on fertility of these mice are reported differently by different groups, possibly due to different 
backgrounds of the mice. Unchanged litter size in G1 and G2 TERT-/- mice (progeny from 
a chimeric and a wild-type C57Bl/6 mouse) has been reported by some97, while others 
experienced dramatically reduced litter size in G2 TERT-/- mice on a pure C57Bl/6 
background.98 Indisputable is the fact that later generation TERT-/- and TERC-/- mice both 
have considerably shorter telomeres than their wild-type litter mates.98-100
In general, homozygous TERT and TERC deficient mice display a similar phenotype. 
However, one remarkable difference between heterozygous TERT and TERC deficient 
mice has been observed. In contrast to TERC+/- mice, TERT+/- mice do not have detectable 
defects in telomere maintenance and elongation. In both heterozygous mice, the mRNA 
levels of their knocked out gene are approximately 30–50% of that of wild-type mice. The 
differences are therefore unlikely to be attributable to differences in target gene expression. 
Presumably, both TERC and TERT are essential for telomere maintenance and elongation, but 
in contrast to TERT, gene copy number and transcriptional regulation of TERC are limiting 
for telomerase activity.100, 101
Hypertension
Several cross-sectional human studies associate blood pressure parameters with telomere 
length of circulating leukocytes.55, 102 Only one study is available evaluating blood pressure 
in telomerase-deficient mice.103 In conscious mice, tail sphygmomanometry revealed that 
TERC-/- mice from G1 showed higher systolic blood pressures compared with wild type. 
In G3 mice, both systolic and diastolic blood pressures were increased compared with 
wild-type and G1 mice. Studying anaesthesized G3 and wild-type mice with invasive 
haemodynamic studies did not show functional modifications in the nitric oxide system or 
the responsiveness to angiotensin II. Thus, the differences in blood pressure do not seem to 
be attributable to these two systems. Interestingly, the response to endothelin—a powerful 
39
Telomere biology in healthy aging
2
vasoconstrictor—was diminished in G3. In concordance, treatment with bosentan, 
an endothelin receptor antagonist, resulted in a more pronounced drop of blood pressure 
in G3 mice compared with wild-type. Furthermore, plasma and urine endothelin levels 
were gradually and significantly increased in G1 and G3 mice. To further explore the role 
of endothelin in the observed differences in blood pressure between TERC-/- and wild-type 
mice, mRNA expression of endothelin converting enzyme (ECE) was measured. TERC-/- 
mice showed higher mRNA expression of ECE-1 and specific inhibition of ECE only reduced 
blood pressure in TERC-/- mice. In vitro experiments with transfection of deletion mutants 
of the ECE-1 promoter suggested that the AP-1 binding sequence of the ECE-1 promoter is 
involved, so that transcriptional control of ECE-1 may be disrupted in TERC-/- mice.103 Whether 
long-term treatment with endothelin receptor blockers is beneficial in TERC-/- mice remains 
to be determined. In addition, this functional data obtained in the TERC-/- mice have not 
been translated back to human studies, meaning we do not know yet whether ECE activity 
is also involved in the association between hypertension and telomere length in humans.
Atherosclerosis
The association between reduced telomere length in leukocytes with the development 
and presence of atherosclerotic manifestations in humans is demonstrated by several 
independent groups.72, 73, 104, 105 As mice in general are resistant to the development of 
atherosclerosis,106 many groups are using the apolipoprotein-E (ApoE)-deficient mice, 
which do develop atherosclerosis when exposed to a high fat diet.107 Interestingly, 
ApoE-/- mice were inter-crossed with TERC-/- mice to study the effects of telomeres 
on the development of atherosclerosis.108 Fourth generations of TERC-/-ApoE-/- and 
TERC+/+ApoE-/- mice were challenged with a high cholesterol high fat diet. Remarkably, 
generation four (G4) TERC-/-ApoE-/- mice developed less atherosclerotic lesions compared 
with G4 TERC+/+ApoE-/- mice (Table 3). In addition, the atherosclerotic plaques of G4 
TERC-/-ApoE-/- mice were morphologically in a less advanced stage of atherosclerosis, 
compared with G4 TERC+/+ApoE-/-. This suggests that the absence of telomerase activity 
is protective for atherosclerotic disease. These observations could not be attributed to 
differences in serum cholesterol levels.108 It was also observed that the proliferative capacity 
of macrophages and lymphocytes was decreased in G4 TERC-/-ApoE-/- mice compared with 
G4 TERC+/+ApoE-/-, suggesting reduced inflammatory capacity. This might explain the 
differences in atherosclerotic manifestations in this experimental model, since progression 
of atherosclerosis is partly dependent of functional immunocompetent cells.108
Angiogenesis
Evidence for involvement of telomerase in angiogenesis has been provided by adenovirus-
mediated transfer of TERT in the rat hind limb ischaemia, which enhances capillary density 
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Table 3. Mouse models of telomerase manipulation and the cardiovascular phenotype.
Model Animals (genetic 
background)




Mouse, TERC−/− (C57Bl/6 
background)
Hypertension 103
Decreased angiogenic potential 
(>generation 3)
110
Inflammation: decreased Lymphocyte 
(T and B) proliferative response
116
Mouse, TERC−/− (mixed 
background)
Myocyte hypertrophy, left ventricular 
failure and dilatation
111
Decreased angiogenic potential 
(>generation 3)
110
Mouse, TERT−/− (mixed 
background)
Inhibited upregulation of telomere-
stabilizing protein TRF2 following 
exercise. No protection against 
doxorubicin-induced cardiomyopathy
112
Mouse, TERC−/− ApoE−/− Less atherosclerosion, decreased 
proliferative capacity of 
inmunocompetent cells
108
Mouse, TERC−/− Atm−/− Depletion of haematopoietic progenitor 
cells
123
Mouse, TERC−/− Wrn −/− Development of diabetes mellitus type 2 124
TERT depletion Rat, transfection of double 
negative TERT
Abrogation of angiogenesis 109
TERT 
overexpression
Mouse, transfection of 
cardiac-specific TERT
Myocyte hypertrophy, left ventricle 
hypertrophy without diminished 
function, increased cardiac ischemia 
tolerance in myocardial infarction
125
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in the ischaemic tissue.109 Also, TERC-/- mice have been studied using both matrigel implants 
and murine melanoma grafts.110 In an in vivo matrigel assay, late generation TERC-/- mice 
showed diminished angiogenic potential compared with wild-type mice. Early generation 
TERC-/- mice, who have normal telomere length, did not have impairment of angiogenesis 
as assessed by the in vivo Matrigel assay.110 This suggests that short telomere length limits 
the angiogenic potential, and not the absence of functional telomerase itself. Also an in 
vivo angiogenesis model using murine melanoma cells showed decreased tumor formation 
efficiency and growth rate in later generations TERC-/- mice. Microvessel density in tumor 
cryosections was stained with an anti-CD31 antibody—an endothelial cell marker—and it 
was shown that the microvessel density of G5 TERC-/- tumors was only half of the wild-type 
and G2 TERC-/- tumors.110
Cardiac myocytes and ventricular failure
The effects of telomerase deficiency on cardiac myocyte size, number, proliferative 
potential, and myocyte apoptosis has been studied in combination with cardiac function in 
G2 and G5 TERC-/- mice of the original mixed background and compared with wild-type 
mice. The progressive decrease of telomere length in cardiomyocytes of successive 
generations of TERC-/- mice was associated with an increase of p53 expression.111 G5 TERC-/- 
mice suffer from severe left ventricular failure, characterized by increased end diastolic left 
ventricular pressure, decreased maximally developed left ventricular pressure and disturbed 
contractility and relaxation of the left ventricle. These mice also showed anatomical changes 
of the heart, similar to dilated cardiomyopathy in human, together with decreased total 
number of myocytes and increase of myocyte hypertrophy. In addition, apoptosis of 
myocytes was an approximate 40% greater in G5 TERC-/- mice, compared with wild-type 
and G2 TERC-/- mice.111 In G2 TERC-/- mice, only a slight decrease in left ventricular pressure 
compared with wild-type mice was observed.111 These data suggest that late generation of 
TERC-/- mice spontaneously develop pathological cardiac remodelling and severe ventricular 
dysfunction. Another study showed that exercise increased TRF2 expression and prevented 
doxorubicin-induced cardiac apoptosis in wild-type mice, but not in TERT-/- mice. This 
suggests that, in absence of telomerase, upregulation of telomere-stabilizing proteins is 
challenged and cardiac apoptosis is more severe.112
In conclusion, telomerase-deficient mice provide a model to study the efficacy of 
telomerase-based therapies for heart failure. However, it should be taken into account that 
the majority of patients who develop heart failure have coronary artery disease.
Stem cell biology and tissue regeneration
A key process in tissue and organ homeostasis is the mobilization of stem cells for 
maintenance and repair. Evidence is supporting a role for bone marrow derived cells in the 
maintenance and regeneration the endothelium.113 More controversial is whether the heart is 
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also harbouring progenitor cells in adult life.114, 115  The TERC-/- mice have provided us with 
more insights in the role of telomerase and telomere length in several well-characterized 
stem-cell subtypes, including haematopoietic, epidermal, and neural stem cells.
Haematopoietic progenitor cells from G1 TERC-/- mice have a normal capacity to grow 
and differentiate in vitro. Mature haematopoietic organ structure and function seem to be 
well compensated in TERC-/- deficient mice, as no changes in peripheral blood count and 
profile were observed through successive generations and mature immunocytes show 
normal responses to mitogenic or infectious stimuli.116 However, in vitro haematopoietic 
colony-forming unit (CFU) assays revealed that later generation TERC-/- mice have 
a significant decrease in total number of CFU-granulocyte–monocyte, CFU-granulocyte, 
-erythrocyte, -monocyte, -megakaryocyte, and decreased high-proliferative-potential colony 
forming cell colonies.116 In addition, serial and competitive transplantations of TERC-/- 
bone marrow stem cells showed reduced long- term repopulating capacity compared with 
wild-type cells.117, 118 This indicates that long-term renewal of haematopoietic stem cells is 
compromised upon telomere loss.
In different generations of TERC-/- inbred mouse, the epidermal stem cell number has 
been compared.119 In G1 and even more pronounced in G3 TERC-/- mice, greater numbers 
of epidermal stem cells were present in the bulge area of the hair follicle. Interestingly, the 
epidermal stem cells in TERC-/- mice showed a defect in their mobilization. Coincidentally, 
the proliferation index in different compartments was lower than that of wild-type follicles. 
In addition, in vitro culture of keratinocytes from G1 and G3 TERC-/- mice formed fewer and 
smaller colonies than those of wild type.119 Thus, epidermal stem cells in TERC-/- mice are 
less functional than in wild-type, and the increased numbers of epidermal stem cells in the 
TERC-/- mice are possibly due to accumulation in the follicles, as the epidermal stem cells 
have impaired capacity to mobilize.
Although bone marrow and stem cells are considered important in the pathogenesis 
and possible treatment of cardiovascular disease, including atherosclerosis and heart failure, 
studies focussed on the role of telomere biology are lacking. In this regard also, the TERC-/- 
model provides a good model to study the efficacy of stem cell-based therapies for heart 
failure.
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Conclusions and future perspectives
Telomere biology is involved in biological aging and disease processes. Experimental 
evidence suggests that telomere shortening, uncapping, and cellular senescence results in 
an “aging” phenotype.33 The exhaustion of progenitor cells and the cumulating of senescent 
cells might explain the decline in organ function associated with aging. Shorter telomere 
length has been associated with several age associated diseases, including cancer, diabetes, 
atherosclerosis, and heart failure. To gain more insights in the role of telomere biology in 
the aging process of humans, we are still in need of large population based cohorts with 
telomere length and telomerase activity measurements at multiple time-points. If telomere 
biology can be proven to be causally involved in the development and progression of these 
age-associated diseases, it will pave the way for new therapeutic or preventive strategies. 
For example, telomerase or telomere length could be targeted in the emerging stem cell 
therapies for organ dysfunctions.
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Telomerase knockout mice 
have an impaired 
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Physical activity increases life span and is thought to postpone biological aging and aging 
associated diseases. Telomerase is an essential enzyme in telomere maintenance and in its 
absence biological aging is accelerated. Here we investigated the effects of physical exercise 
on cardiovascular function in wild type (WT) and telomerase deficient mice (TERC-/-).
Methods and results 
C57BL/6 (WT),  TERC-/- generation 2 (G2), and generation 3 (G3) mice were randomized 
to voluntary physical activity (unlimited access to a running wheel) or sedentary ‘life-
style’. The voluntary running wheel performance of TERC-/- mice was considerably lower 
compared to WT mice. Differences in left ventricular function did not explain the difference 
in physical activity. Physical activity was associated with a decreased resting heart rate in 
WT and TERC-/- mice. In WT but not in TERC-/- mice, physical activity improved endothelial 
function. Histological analysis of the gastrocnemius muscles showed a marked decrease of 
the high oxidative capacity fibers in sedentary TERC-/- G3 mice, but this was completely 
restored in the TERC-/- G3 running group.
Conclusions
Lack of telomerase expression is associated with decreased voluntary wheel-running 
performance in a murine exercise model. There were no gross abnormalities in cardiac 
function, but a combination of multiple small changes, including a difference oxidative 
capacity of the muscle fibers and maximal endothelial vasodilatation, might account for the 
decreased exercise activity.  
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Introduction
Regular non extensive exercise is associated with an increased life span1 and is thought 
to postpone the biological aging process and aging associated diseases. Voluntary regular 
exercise has been reported to reduce cardiovascular events.2, 3 In diabetic patients regular 
physical activity also improves insulin sensitivity.4, 5 
The mechanisms trough which physical activity exerts its beneficial effects are not 
completely elucidated. Paradoxically, more exercise increases physiological stress and 
increases the level of reactive oxygen species (ROS) leading to DNA damage.6 On the other 
hand, exercise causes upregulation of the anti-oxidative stress related pathways and may be 
protective. It has been suggested that the effects of exercise might be U-shaped and that 
excessive exercise will not have beneficial effects or might even be harmful.7 
Adults with higher levels of physical activity have on average longer telomeres than 
inactive age matched controls.8, 9 However in a Chinese population after the age of 70, 
telomere length was not associated with exercise anymore.10
Recent studies show that exercise increases telomerase activity in cardiac and vascular 
tissue of mice and increases telomere-stabilizing proteins in leucocytes of athletes. Increase 
in telomerase is associated with decreased levels of apoptosis and senescence in the different 
organs.11, 12 Shorter telomere length has been associated with cardiovascular diseases 
including heart failure13, hypertension14, 15 and atherosclerosis.16, 15 Telomerase deficient 
mice (TERC-/-) show an accelerated aging phenotype that is accompanied by hypertension 
and decreased angiogenic potential.17 We investigated whether physical exercise can protect 
telomerase deficient mice from accelerated deterioration in cardiovascular function. 
Methods
Animals 
The investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 
1985). Male and female C57Bl/6j WT mice and C57BL/6 mice lacking the RNA component 
of the enzyme telomerase (TERC-/-)18 generation 2 (G2) and TERC-/- generation 3 (G3) 
were obtained from Centro Nacional de Investigagiones Oncológicas (CNIO) Spain. During 
the entire experiment, animals were kept on a 12 hour light, 12 hour dark cycle with ad 
libitum access to food and water.
Voluntary exercise
At the age of 12 weeks, 4 animals (2 male, 2 female) from WT, G2 and G3 groups were 
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subjected to 4 weeks of voluntary exercise. The animals were individually housed and the 
cages were equipped with a running wheel and a tachometer. Daily notations of the time 
spent in the wheel, the distance travelled and the average speed were taken. Sedentary 
animals were single caged for the same time period as exercise animals. 
Echocardiographic and hemodynamic measurements
Cardiac dimensions were measured when the animals were subjected to voluntary 
wheel running or animals were individually caged as sedentary controls. Cardiac dimensions 
were measured using transthoracic echocardiography with a 14 MHz transducer (Vivid 7, 
GE Healthcare, Diegem, Belgium), mice were anesthetized using isoflurane (2% in O
2
), 
temperature was maintained by placing the mouse on a heating pad. Short-axis view and 
M-mode tracings were used to determine end-diastolic and systolic left ventricle (LV) 
interventricular septal thickness (IVS). Mitral valve Doppler signals were used to establish 
E/A ratio. Relative wall thickening was calculated by the formulas: wall thickness changes, 
ΔWT = ESWT (end systolic wall thickness) – EDWT (end systolic wall thickness), and 
relative wall thickness, %WT = 100% * (ΔWT/EDWT).
Heart rate (HR) and mean arterial pressure (MAP) were measured at sacrifice using 
a Millar catheter (Mikro-tip 1.4F; SPR-839, Millar Instruments, Houston, TX, USA). Mice 
were anesthetized as described above and the right carotid artery was inserted with the 
pressure transducer catheter. After the hemodynamic measurements, mice were sacrificed 
by excision of the heart. 
Vascular function
Thoracic aorta was collected after sacrifice, carefully cleaned and thereafter mounted on 
a small wire myograph (Danish Myo Technology A/S, Aarhus, Denmark). After normaliza-
tion, vessels were pre-contracted with Phenylephrine (PE) (Sigma-Aldrich, Zwijndrecht, 
The Netherlands) and vasodilatation was measured by dilating the vessel with increasing 
concentrations of acetylcholin (Ach) (Sigma-Aldrich), endothelium-independent relaxa-
tion was measured by 0.1 mmol/L sodium nitroprusside (Sigma-Aldrich).
Histology
Sections for histological staining were cut at 10 µm thick from frozen gastrocnemius 
muscle and were place on polysine coated microscope slides. NADH tetrazolium reductase 
(TR) staining was carried out by incubating slides for 45 minutes with NADH-TR reaction 
solution (0.2 mol/L Tris, 1.5 mmol/L NADH and 1.5 mmol/L nitrotetrazolium blue) followed 
by 4% formaldehyde fixation and mounting the slides with Kaiser’s glycerol gelatine (Merck 
KGaA. Darmstadt, Germany) Fibers that stained moderately or strongly for NADH-TR were 
counted positive for NADH-TR, from each animal at least 70 fibers were counted.
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Telomere length measurement by PCR
Telomere length was determined in genomic DNA isolated from the spleen, by 
Nucleospin tissue kit (MACHEREY-NAGEL, Düren, Germany). The spleen was used, as 
this organ contains a high amount of lymphocytes, which would best represent blood 
measurements. Telomere length was determined by adapting the previous described 
protocol.13 In short, relative telomere length was determined with ABsolute QPCR SYBR 
Green ROX Mix (Abgene, Epsom, United Kingdom) in the presence of 50 ng genomic DNA 
and 200 nmol/L forward and reverse primers. Real-Time PCR was conducted on the Biorad 
CFX384 (Biorad, Veenendaal, The Netherlands). Telomere (TEL) quantity was normalized 
by correcting for the single copy gene quantity of hemoglobin (HBB). Primer sequences 
can be found in Table 1. 
RNA analysis
Total RNA from tissues was extracted with TRIzol reagent (Invitrogen Corporation, 
Carlsbad, CA, USA). cDNA synthesis was performed using standard methods. Gene 
expression was measured with ABsolute QPCR SYBR Green ROX Mix (Abgene) in the 
presence of 10 ng cDNA and 200 nmol/L forward and reverse primers. Real-Time PCR was 
conducted on the Biorad CFX384 (Biorad). ANP levels were calculated by the CFX manager 
version 1.1 (Biorad) software, by the delta delta Ct method. GAPDH and β-actin levels were 
used as housekeeping genes. Primer sequences can be found in Table 1. 
Table 1. Primer sequences used in Real-Time PCR 
Primer Forward Reverse








Abbreviations: TEL: telomere, HBB: hemoglobin, ANP: atrial natriuretic peptide, 36B4: acidic ribosomal 




Results are expressed as mean ±SE. Groups were compared by unpaired Student’s t-test 
or one-way ANOVA with Dunett post-hoc correction, non-Gaussian distributed data was 
compared by Kruskal-Wallis H test, followed by individual comparisons of means (Mann-
Whitney U). Values of P<0.05 were considered statistically significant.
Results
TERC-/- mice have shorter telomere length
Telomere length was measured in the spleen of the different animal groups to establish 
relative telomere length differences between WT and TERC-/- G2 and G3 animals. As shown, 
in figure 1, relative telomere length in TERC-/- G2 mice was on average 2.2 fold lower than 
in WT mice. In TERC-/- G3 mice telomere length had further shortened and was on average 
1.8 fold lower as compared to TERC-/- G2 mice (Figure 1). 
TERC-/- mice have an impaired running performance
WT and TERC-/- mice were solitary housed and half of the cages were equipped with 
a running wheel, allowing voluntary exercise to half of the animals. All mice that had access 
to a running wheel also made use of it. In the first week of exercise, there was no difference in 
distance, time spent in the running wheel and average running speed between the different 
groups (Figure 2A-C). However, after the first week, differences between the groups became 
visible. Whereas the WT mice significantly increased the running distance in the second week 














Figure 1. Telomere length in WT 
(n=7) and TERC-/- G2 (n=7) and 
TERC-/- G3 (n=7) mice. Relative 
telomere length measured by 
Real-Time PCR in genomic DNA 
isolated from the spleen. Data are 
depicted as a boxplot with median 
and interquartile range, whiskers 
represent minimum to maximum. 
* = P<0.05 compared to WT group, 
# = P<0.05 compared to G2 group.
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did not increase their running distance (Figure 2A). After week one, the running wheel 
time became significantly different between WT mice and TERC-/- mice, this was mainly 
due to a decline in running time by the TERC-/- mice (Figure 2B). Based on the running 
wheel time and the total running distance we were able to calculate the average running 
speed during the different weeks. This revealed that all animal groups increased the average 
speed in their 4 weeks running time. This increase was, however, significantly higher in the 
wild type mice as compared to the TERC-/- mice (Figure 2C). Although not significant, we 
like to note that the TERC-/- G3 group performed less than the G2 group animals in all these 
parameters at all time points. Together these data indicate that TERC-/- G2 and G3 animals 
have a decrease in running wheel performance compared to WT animals. 
TERC-/- and WT mice have similar cardiac function after 4 weeks of exercise
Next we investigated parameters that could potentially account for the differences 
in running wheel performance between WT and TERC-/- mice. Blood parameters were 
measured to determine whether signs of anemia or increased inflammation in TERC-/- mice 
were present (Table 2). Red and white blood cell counts were comparable between all 
three groups, and although hemoglobin and hematocrit values were somewhat elevated 
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Figure 2. Exercise characteristics of the WT 
(circles), TERC-/- G2 (squares) and TERC-/- G3  
(triangles) mice during 4 weeks of voluntary 
running. A. Average distance travelled over 
24 hours per group per week in arbitrary 
units (AU). B. Average time spent in running 
wheel during 24 hours per group per week, 
in arbitrary units (AU). C. calculated average 
speed per 24 hours per group per week in 
arbitrary units (AU).  Data expressed as mean 
±SE, * = P<0.05 compared to G2 group,  
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in the G2 running animals compared to the WT running animals and platelet count was 
elevated in G3 running animals compared to WT running animals there were no consistent 
differences. 
To determine if  TERC-/- mice had aberrant cardiac function before exercise, heart func-
tion was measured by echocardiography (Table 3). There was a difference in the percentage 
fractional shortening in TERC-/- mice compared to the WT animals. This was borderline not 
significant (P=0.054) for WT vs. G2, but significant for WT vs. G3 (P=0.044). These dif-
ferences in fractional shortening did, however, not result in a changed ejection fraction or 
in a change in the cardiac output after correcting for body weight (Table 3).
Exercise can influence cardiac function resulting in physiological cardiac hypertrophy, 
which is characterized by an increased heart weight and an increase in cardiac atrial 
natriuretic peptide (ANP) expression levels.19 After 4 weeks of voluntary exercise cardiac 
parameters were measured for all groups (Table 4). In line with previous studies with the 
TERC-/- mice, body weight decreased with each generation. Heart weight corrected for 
tibia length, a measurement of hypertrophy, did not show differences between the groups 
(Figure 3A). Also blood pressure and ANP levels measured in mRNA isolated from the left 
ventricle did not change between the groups (Table 4). These parameters indicate there was 
no hypertrophy in any of the groups.
Voluntary exercise resulted in all three groups in a 17% drop in the resting heart rate, 
which was measured at sacrifice at the end of the running period (Figure 3B), which was 
significant for the G2 group.  Thus, although TERC-/- mice had a lower exercise performance, 
Table 3. Cardiac characteristics at the beginning of the voluntary wheel running, measured by 
echocardiography
WT (n=7) G2 (n=8) G3 (n=8)
LV IVSs (mm) 1.20 ±0.22 1.08 ±0.49 1.00* ±0.50
LV IVSd (mm) 0.68 ±0.26 0.61 ±0.40 0.60 ±0.20
relative wall thickening (%) 76.87 ±8.89 78.91 ±10.51 67.14 ±8.02
ejection fraction (%) 73.57 ±4.72 61.19 ±3.21 60.26 ±3.99
fractional shortening (%) 38.47 ±4.25 28.36 ±2.10 28.00 ±2.60*
cardiac output (ml/min) 21.40 ±1.48 15.50 ±1.98* 16.55 ±1.37
cardiac output corrected for 
body weight (ml/min/gr)
0.87 ±0.05 0.68 ±0.08 0.85 ±0.09
Data presented as means ±SE *P<0.05 versus WT, one-way ANOVA with Dunett post-hoc correction.
Abbreviations: LV: left ventricle, IVSs: interventricular septal thickness at systole, IVSd:
interventricular septal thickness at diastole.
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a similar drop in resting heart rate was observed, suggesting that a similar physiological 
effect occurred in these mice.
Exercise improves maximum vascular dilatation in WT mice only
As exercise is potentially beneficial for endothelial function we measured endothelial 
function in the thoracic aorta by small wire myograph (Figure 4). Voluntary exercise 
improved acetylcholine induced maximal vasodilatation in PE pre-contracted vessels in the 
WT animals from 68.6 ±2.7% in the non-running group to 86.6 ±2.3% in the running 
group (P=0.004). In TERC-/- animals maximal relaxation of the sedentary groups was 
comparable to the sedentary WT group. No increase in maximal relaxation was, however, 
observed in the running TERC-/- groups. Thus, exercise improved endothelial function only 
in WT animals.
Sedentary TERC-/- G3 mice have lower number of oxidative fibers 
Since abnormal muscle function, like muscular dystrophy or atrophy, could affect exercise 
performance we analyzed muscle structure. Histological analysis of the gastrocnemius, 
a major hind leg muscle in the mice, was performed. Hematoxylin eosin staining and 
Gomori trichrome staining of the muscles did not indicate any sign of muscular atrophy 
or dystrophy in the TERC-/- animals (data not shown). To determine the oxidative state of 
the fibers we performed a NADH-TR staining, which stains the high oxidative rich fibers. 
Differences were visible in the number of NADH-TR positive fibers in the sedentary G3 
Figure 3. Cardiac parameters measured in sedentary and exercised WT and TERC-/- mice.  A. Heart 
weight tibia length ratio after 4 weeks of exercise. B. Heart rate measured under anesthesia at the 
end of the end of the protocol. Data are expressed as mean ±SE, black bars represent non-running 
animals, white bars represent voluntary wheel running animals.  * = P <0.05 compared to sedentary 
control of the same group.




























































































































































































































































































































































































































































TERC-/- animals, which were less abundant as compared to WT and TERC-/- G2 animals. 
(Figure 5A-B) In the running group of G3 TERC-/- animals, this difference was, however, 
normalized to levels comparable to WT and G2 TERC-/- (Figure 5A-B). 
Discussion
Here we investigated the effects of voluntary exercise on cardiovascular function in 
telomerase deficient mice. The most striking observation was the reduced exercise perfor-
mance of the TERC-/- mice in comparison to WT mice. In order to explain this difference we 
measured multiple functional cardiovascular parameters, including echocardiograph, and 
in vitro vascular function measurements. Only endothelial relaxation was markedly different 
between WT and TERC-/- mice after running. WT animals showed improved vascular relaxa-
tion after running, whereas this improvement was absent in TERC-/- animals. In addition we 
observed some change in the number of oxidative fibers in the musculature of TERC-/- G3 
sedentary animals, and this was normalized in the TERC-/- G3 running animals.
During the four weeks of voluntary exercise there was a significant difference in running 
wheel performance between TERC-/- animals and WT mice. The TERC-/- mice ran shorter 
distances and also spent less time in the running wheel. TERC-/- mice were somewhat smaller 
and had a reduced body weight compared to WT mice. Since Dohm et al describe that they 
did not find any evidence that body mass was a covariate that influenced performance20, we 
believe it is unlikely that size differences could explain performance differences. 
Running wheel performance of TERC-/- G3 mice was less than TERC-/- G2 mice and 
Figure 4. Endothelial function 
measurements by small wire myograph. 
Maximal vasodillatation of thoracic 
aorta by Ach after PE (10-4 mol/L) 
pre-contraction. Graph shows the 
difference in relaxation of the different 
groups on 10-4.5 mol/L Ach. Data 
expressed as mean ±SE, black bars 
represent non-running animals, white 
bars represent voluntary wheel running 
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although the differences were not significantly different G3 mice tended to perform worse 
on all measured exercise parameters. As expected, G3 animals have shorter telomeres 
compared to G2 and WT animals. This suggests that the progressive worsening of exercise 
performance is associated with the shortening of telomeres and not telomerase activity per se. 
Werner et al. described that voluntary wheel running performance of G2 TERT-/- mice was 
comparable to WT control mice.11, 12 In contrast to our TERC-/- mice, which lack the RNA 
component of the telomerase enzyme18, the TERT-/- mice of Werner lack the catalytic subunit 
of telomerase.21 Both animal models therefore lack telomerase activity and although the 
relative telomere shortening between both models has never been directly compared, it can 
be expected that this is similar. The RNA component of telomerase might have additional 
functions and together with telomere shortening it results in a decreased exercise activity. 
Gene array analysis of WT and G1 generations of  TERC-/- and TERT-/- animals did, however, 
not reveal any expression differences22, which suggests no major differences in TERT-/- and 
TERC-/- function. As it has been described that exercise performance is also influenced by the 
genetic background of inbred strains it is of importance to note that this might also explain 
some of the differences found between TERC-/- and TERT-/- mice.23, 24 Alternatively, we cannot 
exclude that differences in housing conditions between our study and previous studies 
Figure 5. Oxidative fiber capacity 
in gastrocnemius in sedentary and 
voluntary wheel running mice. 
A. Percentage NADH-TR positive 
fibers in sedentary and running WT 
and TERC-/- mice. Data expressed 
as mean ±SE, black bars represent 
non-running animals, white bars 
represent voluntary wheel running 
animals. * P<0.05 compared to 
WT sedentary animals. B. NADH-
TR staining in TERC -/- G3 mice. Left 
picture is from sedentary TERC -/- G3 
mice, right picture is from voluntary 
running TERC -/- G3 mice. Fibers 






























might have attributed to the differences between TERC-/- and TERT-/- mice and therefore, in 
future studies it will be important to compare TERC-/- and TERT-/- strains directly with each 
other. In addition for future experiments it would be interesting to test TERC-/- and TERT-/- 
mice in non-voluntary exercise models and also measure maximum force generated during 
exercise and monitor exercise patterns during the day, to get a better understanding of the 
decreased exercise phenotype we observed in TERC-/-.
Although some studies describe that a relative short period of exercise is sufficient to 
increase cardiac hypertrophy19, 25, we did not notice a change in cardiac hypertrophy in 
any of the animals after four weeks of exercise, which is in line with the studies of Werner 
et al. and Zahn et al. who also noticed no signs of cardiac remodeling.11, 26 There was no 
change in the heart weight to body weight ratio and we did not observe an increase in ANP 
expression or blood pressure at sacrifice. Although we did not observe differences in cardiac 
parameters, we did observe vascular effects. Exercise improved endothelial acetylcholine 
induced maximal vasodilatation in the WT mice, which is in line with previous studies.12, 27 
Interestingly, however, in the TERC-/- mice there was no improvement of the endothelial 
relaxation after exercise. We cannot exclude that this is a resultant of less exercise performed 
by these TERC-/- animals. However, there was a similar drop in rest heart rate in WT and TERC-/- 
animals after exercise, suggesting that the exercise induced a physiological effect. 
In old mice, exercise performance is also decreased compared to young animals, but 
interestingly, voluntary exercise is sufficient to improve endothelial vasodilatation to the same 
levels as young mice.27 Strikingly, TERT-/- mice also show an improvement in endothelial 
function after exercise12, this is different to our results in TERC-/- mice and could suggest that 
the potential improvement of endothelial function is essential for exercise performance. 
Endurance exercise is associated with a number of endurance-related muscle adaptations, 
including the heart muscle19, 28-30 and changes in the skeletal muscles where exercise 
increases the slow twitching MHC-type I or IIa muscular fibers, fiber types with a high 
oxidative capacity. The increase of high oxidative fibers is at the cost of the high glycemic 
but low oxidative MHC-type fibers especially IIb fibers.19, 31-34 Voluntary exercise models 
in rodents have shown that these adaptations occur in the tibialis anterior, soleus and 
gastrocnemius of exercised animals.19, 34 In our study we determined NADH-TR percentage 
in the gastrocnemius, a staining that is indicative of the oxidative state of the muscle fiber. 
In the muscle fibers that are preferential for exercise, MHC-type I and MHC-type IIa fibers, 
NADH-TR levels are higher. In our WT running mice we did not see a change in oxidative 
fibers in the gastrocnemius. Absence of a change in oxidative fibers in the gastrocnemius 
was also reported by Allen et al.19, in a comparable 4 week exercise study. We did, however, 
observe a clear decrease of oxidative fibers in sedentary G3 mice, and although these animals 
performed less exercise than the other groups, exercise increased the oxidative capacity of 
the fibers to the same levels as WT and G2 animals. The low oxidative fiber levels in the 
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sedentary G3 animals might be a result of the apparent lower activity of these animals as 
compared to the other sedentary animals. The musculature in TERC-/- G3 mice has, however, 
still the capacity to increase their oxidative capacity. 
The most striking finding in this study was the difference in exercise performance of 
the TERC-/- mice in comparison to WT mice. Although we did not measure a single apparent 
factor that on its own might explain this difference, it might be a cumulative effect of 
multiple small changes between WT and TERC-/- mice. Only a limited number of parameters 
were analyzed and we cannot exclude the possibility that other factors such as potential 
glycemic control, food intake or neurological differences could have more profound effects 
on exercise performance. Our investigations do reveal that no major cardiac abnormalities 
are present in TERC-/- animals up to generation 3.
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 oxidative stress-induced 
endothelial cell senescence
Hisko Oeseburg, Dilek Iusuf, Pim van der Harst, 





Premature aging (senescence) of endothelial cells might play an important role in the 
development and progression of hypertension and atherosclerosis. We hypothesized that 
bradykinin, a hormone that mediates vasoprotective effects of ACE inhibitors, protects 
endothelial cells from oxidative stress-induced senescence.
Bradykinin treatment (0.001 nmol/L – 1 nmol/L) dose-dependently decreased senescence 




 in cultured bovine aortic endothelial cells as witnessed by 
a complete inhibition of increased senescent cell numbers and a 34% reduction of the levels 




 induces senescence through 
superoxide-induced DNA damage, single cell DNA damage was measured by comet assay. 
Bradykinin reduced DNA damage to control levels. The protective effect of bradykinin also 




 treated BAEC in an in vitro endothelial 
injury model, or “scratch” assay. The protective effect of bradykinin was abolished by the 
bradykinin B2 receptor antagonist HOE-140 and nitric oxide production inhibitor L-NMMA. 
Therefore, we conclude that bradykinin protects endothelial cells from superoxide-induced 
senescence through bradykinin B2-receptor- and nitric oxide-mediated inhibition of DNA 
damage.
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Introduction
Aging-related vascular dysfunction is believed to be an important contributor to vascular 
pathogenesis and a worsened prognosis.1, 2 Hypertension, one of the main risk factors for 
a number of cardiovascular diseases, is characterized by an accelerated development of 
age-related endothelial dilator dysfunction.3 Therefore, the development of therapeutic 
strategies directed against age-related endothelial function decline will be an important 
step toward prevention and treatment of age-related vascular disease such as hypertension 
and coronary artery disease.
Endothelial cell senescence is a cyclin-dependent kinase inhibitor 1A (p21) proliferative 
arrest4 that can be induced by DNA damage caused by exposure to reactive oxygen species 
(ROS).5 There are several reasons to assume that endothelial cell senescence is involved in 
vascular pathogenesis. Senescent endothelial cells show deleterious functional changes (e.g., 
decreased release of endothelial-derived relaxing factors, increased release of endothelial-
derived constricting factors and increased production of molecules that are associated 
with inflammation).6, 7 These features are reminiscent of the aberrant endothelial changes 
observed in aging and atherosclerosis.8 Moreover, an increase of senescent endothelial cells 
and senescence markers is observed in the vasculature of atherosclerotic patients and in 
aged rodents with endothelial dysfunction. 8, 9
Angiotensin-converting enzyme (ACE) inhibitors effectively protect against the 
progression of chronic atherosclerotic disease, endothelial dysfunction, and age-related 
vasodilator dysfunction.10, 11 The therapeutic effect ACE inhibitors involves a multitude 
of mechanisms including an increase of bradykinin (BK) levels.12, 13 BK is a vasodilator 
hormone which exerts its vasomotor functions through the increase of the production and 
release of endothelial-derived relaxing factor14, which takes place through the stimulation 
of endothelial bradykinin B2 receptors. However, the mere stimulation of vasorelaxation is 
a poor explanation of how BK would contribute to the improved prognosis that is brought 
about by ACE inhibitor treatment. 
Interestingly, endothelial senescence can be prevented by increasing nitric oxide (NO)15, 
one of the main relaxing factors stimulated by BK. Moreover, aging is associated with 
a decreased availability of cardiac bradykinin B2 receptors16 and in some occasions with 
a blunted endothelium-dependent vasodilator response to BK.17, 18 In addition, combined 
B2 receptor knock-out and diabetes in mice leads to an accelerated aging phenotype which 
is coupled to an increase of oxidative stress and an increase in ACE enzyme levels.19 Therefore, 
the protective effect of BK might also relate to prevention of cellular senescence, in particular 
of the endothelium. Hence, we evaluated the effects of BK pretreatment on endothelial cell 





Primary bovine aorta endothelial cells (BAEC, Tebu-Bio, Heerhugowaard, the 
Netherlands) were cultured in DMEM (Gibco, Breda, the Netherlands), supplemented with 
10% Fetal Bovine Serum (PAA laboratories, Cölbe, Germany), 100 units/ml of penicillin 
and 100 µg/ml streptomycin (Gibco) in a humidified incubator at 37°C and 5% CO
2
. 
When cells reached confluence, they were sub-cultured in a 1:10 ratio. Experiments were 
conducted on cells with a passage number between 3 and 9.
ROS induced senescence and pharmacological studies
BAEC cells, 24 hours after seeding 3000 cells per well in 24- wells clusters, were exposed 




 (Merck, Amsterdam, the Netherlands), to induce DNA 
damage and senescence.  After 1 hour the medium was replaced with normal medium. Various 
concentrations of BK (Sigma-Aldrich, Zwijndrecht, the Netherlands) were administered 30 
minutes before induction of senescence. The B2 antagonist, HOE-140 (Sigma-Aldrich), and 
the NO inhibitor L-NMMA (Nω-Methyl-L-arginine acetate salt (Sigma-Aldrich), were added 
5 minutes before BK treatment after which BK was added without replacing the medium. 
At least 3 separate experiments were performed per treatment. 
Evaluation of the number of senescent cells
To determine the number of senescent cells, senescence-associated-β-galactosidase (sa-
β-gal) staining was performed.20 Cells were washed in PBS and fixated in 2% formaldehyde 
and 0.2% glutaraldehyde for 5 minutes at room temperature, washed and incubated for 











), 40 mmol/L citric acid / sodium phosphate 
dibasic at pH 6.0, containing 1 mg/mL X-gal (5-bromo-4-chloro-3-indolyl-D-galactoside). 
Light microscopic pictures were taken on an inverted microscope (Zeiss Axiovert 135M) 
with a 200x magnification and the number of senescent cells was counted per microscopic 
field. In each well 5 random fields were evaluated. 
P21 protein detection
Cultured cells were lysated with 1x SDS sample buffer (62.5mmol/L Tris-HCL, 2% SDS, 
10% glycerol, 50mol/L DTT, 0.01% bromophenol blue). Lysates were analyzed by standard 
Western blotting techniques under denaturing conditions. Membranes were incubated 
overnight at 4 °C with the primary p21 antibody (Santa Cruz Biotechnology, Santa Cruz, 
USA) at a 1:200 dilution. Membranes were reprobed with β-actin antibody (Sigma-
Aldrich) and incubated for 1 hour at room temperature at a 1:10000 dilution. Signals were 
75
Bradykinin protects against endothelial senescence
4
detected by the ECL-detection method and quantified by densitometry. P21 protein levels 
were corrected for β-actin and results are expressed as a percentage off p21 levels of BAEC 
at passage 31, of which cell protein extracts were run in parallel for each blot.
Apoptosis
Apoptosis was determined with the Caspase-Glo 3/7 Assay (Promega, Leiden, the 
Netherlands) 24 hours after treatment. 
In 96-well plates, 50 µl sample was mixed gently for 30 s with 50 µl of Caspase-Glo 
3/7 reagent and incubated for 2 h at room temperature. Apoptosis was determined by 
luminescence of the samples measured using a Victor Wallac Multilabel Counter 1420.
DNA damage assay
DNA damage was determined by comet single cell electrophoresis assay. BAEC cells were 




 and BK, 24 hours after treatment cells DNA damage 
was determined with CometAssay (Trevigen, Gaithersburg, USA). Cells were harvested and 
approximately 700 cells were placed on a CometSlide in LMAgarose. Cells were lysated one 
hour at 4°C in Lysis Solution. Denaturation was performed for 30 minutes in 0.3 mol/L, 
1 mmol/L EDTA pH>13. Electrophoresis was done in 1x TBE (tris-borate-EDTA, pH 8.3). 
Comet slides were stained with SYBR Green and photos were taken at a 100x magnification. 
Pictures were analyzed with CASP 1.2.2 software.21 Experiments were repeated three times 
and in total more than 248 cells were analyzed per treatment group.
In vitro endothelial injury model




, the in vitro scratch 
injury model was used and adapted for BAEC cells. Cells were seeded in a 96-wells cluster 
at a density of 2000 cells per well. Cells were treated 24 hours after seeding. 24 hours after 
treatment a thin line scratch between the cells was created with a 10 mL pipette tip (Greiner 
Bio-One, Alphen aan den Rijn, the Netherlands). After scratching, the wells were washed 
with PBS and fresh medium was added. 7 hours later the wells were fixed for 10 minutes 
with 2% formaldehyde and 0.2% glutaraldehyde. Each treatment was conducted in at 
least 7 wells, divided over two different experiments. Two pictures were taken per well 
and the width of the scratch was measured at 4 points per picture with Image-Pro Plus 
(Media Cybernetics, Bethesda USA) and the means were calculated. Then the means of the 
2 pictures were calculated to obtain n=1.
Statistics
Data represent mean values +/- standard errors of the means (SEM). Comparisons 
between groups were done by one way ANOVA with Bonferroni or Dunnett’s post-hoc 
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To optimally study the effects BK, a protocol for ROS-induced senescence was designed 
in such a way the outcome is not confounded by apoptosis. Therefore, BAEC were exposed 




 for 1 hour and subsequently cultured for 3 days, after 




 dose dependently increased the 
number of senescent cells leading to significant increases at concentrations of 30 and 100 




 of 100 and higher led to 




 was without effect on caspase-3 activity (Figure 1C). 
Figure 1. Low dose of H2O2 induces senescence in BAEC without causing apoptosis. 
A. Representative pictures of SA-β-galactosidase-stained BAEC cells. Left panel: control (no H2O2), 
right panel: 3 days after stimulation with 25 μmol/L H2O2 for 1 hour. B. Number of SA-β-galacto-
sidase-positive cells per microscopic field 3 days after a 1-hour H2O2 treatment. Bars represent 
mean +/- SEMs (*: p<0.05 vs. control, n=6 experiments).  C. Caspase-3 activity, measured as 
luminescence, in BAEC 24 hours after treatment with H2O2 for 1 hour. Bars represent means +/- SEMs 
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. This approach 
warrants that the cell counting procedure and the measured effects and DNA damage is not 
confounded by apoptosis-related changes. 
BK protects against endothelial senescence through B2 receptors




, BAEC cells were 
pretreated with different concentrations of BK (Figure 2A). BK caused a dose-dependent 
decrease in the number of senescent cells, reaching a maximum effect at a concentration 
of 1 nmol/L which fully inhibited senescence. There was no effect of BK on the cells that 





As a secondary variable to assess senescence, p21 expression was measured by western 
blot analysis. P21 is an important mediator of endothelial cell senescence.4 P21 levels were 




. BK (1 nmol/L) fully prevented the 
change in p21 levels, thus confirming the effect observed when counting senescent cells 
(Figure 2B).
Induction of cell proliferation might confound the effects observed on the p21 levels. 
Therefore, we tested the effect of 1 nmol/L BK on proliferation of BAEC, and found no 
proliferative effect of BK after 24 and 48 h (data not shown).
Figure 2. Effects of bradykinin pre-treatment, given 30 minutes in advance, on H2O2-induced 
senescence of BAEC (passage 3 to 9). A. Number of senescent cells 3 days after treatment. Bars 
represent mean values +/- SEMs (* p<0.05 vs. control, n=6 experiments) B. P21 protein levels 24 
hours after treatment. P21 levels were corrected for β-actin levels and expressed as % of p21 levels 
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BK protects against DNA damage
Protection against senescence can take place in a number of ways, one of which is 
protection against DNA damage. Therefore, we measured the effect of 1 nmol/L BK DNA 




 by determining the olive tail moment in a comet assay 




 increased the olive tail moment (Figure 3), thus indicating 
an increase in DNA damage. BK prevented an increase of DNA damage, whilst being without 





BK protects cells from senescence-induced impaired cell migration
To test if senescence and the protective effect of BK altered endothelial cell function, 
the scratch assay, an accepted method to test the ability of endothelial cells to migrate22, 




 showed a reduced ability 










BK protection against endothelial cell senescence depends on BK B2 receptor 
mediated NO release
BK exerts many of its effects in adult tissues through the BK B2 receptor.23 To check if 
the protective effect against senescence is also dependent on the BK B2 receptor we studied 
the effect of the BK B2 receptor antagonist HOE-140 (1 µmol/L) on reduction of senescent 
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Figure 3. DNA damage in BAEC 24 
hours after treatment, measured by comet 
assay. 
A. Example of the BAEC DNA single 
cell electrophoresis. Left panel: control 
(no H2O2), right panel: 1 day after 
stimulation with 25 μmol/L H2O2 for 
1 hour. Olive tail moment is calculated as 
% DNA in the tail x distance to centre of 
gravity of tail. 
B. Olive tail moment, expressed as % 
DNA in the tail x distance to centre 
of gravity of tail.The DNA damage is 
represented as the natural log of the 
olive tail moment. Bars represent means 
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Figure 4. Cell scratch assay with BAEC treated with H2O2 25 μmol/L, BK 1nmol/L or the 
combination. A. Example of cell scratch assay. Left panel, BAEC immediately after making the scratch. 
Right panel, scratch size after 7 hours in untreated BAEC. B. Scratch size in different groups 24 hours 
after treatment. Bars represent scratch width in μm, 7 hours after scratching +/- SEMs (*: p<0.05, 
n=7 experiments).
Figure 5. The role of BK B2 receptor and NO in the protective effect of BK against senescence in 
BAEC. Senescence was measured as the number of SA-β-galactosidase-positive cells 3 days after 
treatment with H2O2. A. Effect of BK-B2 receptor antagonist HOE-140. B. Effect of NO inhibitor 
L-NMMA. Bars represent means +/- SEMs n=6 (*: p<0.05 vs. control, † p<0.05 vs. BK 1 nmol/L). 
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(Figure 5A). As stimulation of this receptor leads 
to the release of NO, we investigated the effect of blockade of NO production by L-NMMA 
(10 µmol/L). L-NMMA inhibited the protective effect of BK (Figure 5B) and had no effect 
in the absence of BK. Therefore, BK protects against senescence through stimulation of BK 
B2 receptor-mediated NO release.
Discussion
We show here that BK protects against ROS-induced DNA damage and endothelial cell 
senescence through BK B2 receptor-mediated NO release. The protective effect of BK is 
associated with a decrease of p21, a cyclin-dependent kinase 1A inhibitor that is normally 
activated by DNA damage. BK also prevents suppression of endothelial cell migration by 
ROS, thus demonstrating the functional importance of the protective effect of BK. These 
observations are in line with studies that explore the role of the kinin system in aging. 
Previously it has been shown that BK B2 receptor knock-out mice display a slightly accelerated 
aging phenotype, as observed by increased alopecia, skin atrophy, kyphosis, osteoporosis, 
lipofuscin accumulation in renal proximal tubule and testicular Leydig cells, and apoptosis 
in the testis and intestine. Importantly, this aging phenotype is strongly promoted when 
BK B2 receptor knockout is combined with diabetes.19 This underlines the importance of 
the coexistence of a risk factor that adds metabolic, oxidative stress during the process of 
premature aging. This process is apparently counterregulated by the kinin system, not only 
in the cardiovascular system, but also in a broader perspective, and this protective role of 
the kinin system seems to depend on protection against ROS-induced DNA damage, as 
witnessed by our present study. 
This study shows that stimulation of a G-protein coupled receptor that leads to eNOS 
activation can protect against endothelial senescence. Although we are not aware of any 
other study showing a similar role of G-protein coupled receptors, the contrary effect, i.e. 
induction of senescence, can result from stimulation of angiotensin II type 1 receptors in 
vascular smooth muscle cells24 and endothelial progenitor cells.25  Therefore, these previous 
studies combined with our present results suggest that intervention through RAS inhibition 
can be dually protective: on the one hand angiotensin II type 1 receptor blockade prevents 
ROS-induced senescence, and on the other hand ACE inhibition protects against ROS-induced 
senescence through stimulation of BK B2 receptor signaling. ACE inhibitors promote BK 
B2 receptor signaling in two ways. The first possibility is an increase of BK levels due to 
decreased metabolism of this peptide hormone.12 The second way is potentiation of the BK 
response through local interactions in endothelial cells that lead to an increased number 
of BK B2 receptor in their affinity state, both in absolute receptor numbers (measured as 
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binding sites) as well as relative to the number of receptors in the low affinity state.26, 27 ACE 
inhibitors might also decrease formation of angiotensin II. However, during ACE inhibition 
angiotensin II levels are rapidly restored through the so-called “ACE escape”, a bypass 
created by alternative metabolic pathways to restore angiotensin II formation.28, 29 Vascular 
angiotensin II responsiveness is associated with an increased risk of future cardiovascular 
events.30 This underscores the potential importance of BK-mediated inhibition of senescence 
as a mechanism that counterbalances the deleterious effects of angiotensin II signaling. The 
interaction between BK and angiotensin II signaling pathways in the control of cellular 
senescence needs to be elucidated, and requires further confirmation in in vivo models and 
patient studies.
The observation in the present study that BK B2 receptor signaling shows a relationship 
with the function of cell cycle proteins such as p21 is not unique. It has been shown that the 
gene encoding for the BK B2 receptor contains a binding motive for p5331, a transcription 
factor that is activated by DNA damage and that plays an important role in regulation of 
p21 and cellular senescence.32 Forced overexpression of p53 in HeLa cells activated the rat 
BK B2 receptor promoter region in reporter constructs. Our present data complement this 
observation in HeLa cells and, taken together, these studies generate the following, simple 
concept: DNA damage leads to p53 activation, which in turn causes upregulation of BK B2 
receptors. As a result BK B2 receptor activity increases, serving as an endogenous protective 
feedback mechanism against further ROS-induced DNA damage, and thus reducing p21-
mediated cellular senescence and loss of cellular function.  This concept becomes even more 
compelling if one considers that cardiac BK B2 receptors decrease with age. This means that 
aging itself leads to a decline of the BK-mediated protection against cellular aging, which 
would lead to a downward spiral of loss of cell function, especially in situations where 
oxidative stress is increased. This is underlined by the finding that combined BK B2 receptor 
knockout and diabetes leads to a progeoid phenotype in mice.19 It is unclear how BK B2 
receptor signaling leads to protection against DNA damage. The fact that NO is involved 
gives directions towards a possible explanation, which is improved DNA repair. NO has 
been described to protect against replicative senescence whilst NO blockade promotes 
senescence, effects that were associated with telomeric DNA repair by telomerase.15, 33 
Other studies contradict this effect of NO on replicative senescence.34 Nevertheless, we here 
show that NO is also involved in ROS-induced senescence and mediates protection against 
the degradation of DNA on a more global chromosomal DNA scale, which might involve 
various DNA repair systems such as double-strand break repair mechanism that were shown 
to mediate the protective effect of statins against vascular smooth muscle cell senescence.35 
Alternatively, BK could activate anti-oxidant pathways. This intriguing question opens an 
opportunity to further explore and understand the importance of the kinin system and the 




Our data show that BK can protect endothelial cells from cellular aging in an in vitro 
model. When combined with the findings of other studies, our findings contribute to a 
novel paradigm that hypothesizes that the kinin system plays an important role in the 
control of progressive loss of function due to the continual DNA damage that occurs during 
aging. The maintenance of a proper function of the kinin system by pharmacotherapy, 
such as ACE inhibition, in the aging population seems crucial. Since the activity of the 
kinin system decreases with aging, supplemental suppression of oxidant stress, e.g. by 
AT1 receptor antagonist therapy, improvement of DNA repair, e.g. by statins35, and proper 
control of diabetes and a healthy life style appears to be indispensable. Furthermore, it is 
worthwhile to explore the reasons for age-related decrease of kinin system activity and 
seek preventive measures. Organ and cell type specificity, and interactions with or effects 
of other vasoactive peptides, such as angiotensins, will need to be addressed. This will help 
to identify new drug targets as well as provide further explanations with respect to the 
beneficial or unbeneficial effects of already applied drug therapies in cardiovascular disease. 
Last but not least, the paradigm presented here needs to be confirmed by clinical data.
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Glucagon-Like Peptide 1 prevents 
ROS induced endothelial cell 
senescence through the activation of 
protein kinase A
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Endothelial cell senescence is an important contributor to vascular aging and is increased 
under diabetic conditions. Here we investigated whether the anti-diabetic hormone, 
glucagon-like peptide 1 (GLP-1), could prevent oxidative stress-induced cellular senescence 
in endothelial cells. 
Methods and results 
 In Zucker diabetic fatty (ZDF) rats, a significant 2-fold higher level of vascular senescence 
was observed with control lean rats. Dipeptidyl-peptidase 4 (DPP-4) inhibition significantly 
increased GLP-1 levels in these animals and reduced senescence almost to lean animal levels. 
In vitro studies with human umbilical vein endothelial cells (HUVEC) cells showed that 




)-induced senescence and was 
able to attenuate oxidative stress-induced DNA damage and cellular senescence. The GLP-1 
analogue exendin-4 provided similar results, whereas exendin fragment 9-39, a GLP-1 
receptor antagonist, abolished this effect. Intracellular signaling by the phosphoinositide 
3-kinase (PI3K)/Akt survival pathway did not appear to be involved. Further analysis 
revealed that GLP-1 activates the cAMP response element-binding (CREB) transcription 
factor in a cAMP/protein kinase A (PKA)-dependent manner, and inhibition of the cAMP/
PKA pathway abolished the GLP-1 protective effect. Expression analysis revealed that GLP-1 
can induce the oxidative defense genes HO-1 and NQO1. 
Conclusions 
Dipeptidyl-peptidase 4 inhibition protects against vascular senescence in a diabetic rat 
model. In vitro studies with human umbilical vein endothelial cells showed that reactive 
oxygen species-induced senescence was attenuated by GLP-1 in a receptor-dependent 
manner involving downstream PKA signaling and induction of anti-oxidant genes. 
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Introduction  
Vascular aging is an important contributor to the progression of diabetes and 
cardiovascular diseases and is associated with a worsened prognosis.1, 2 In diabetes and 
atherosclerosis there is a causal link between endothelial dysfunction and the progression 
of these diseases.1-4 One of the main contributors is the increase in reactive oxygen species 
(ROS), which increases intra-cellular (DNA) damage and ultimately can result in the onset 
of apoptosis or the induction of cellular senescence.5, 6 Increased levels of cellular senescence 
have been observed in the vasculature of patients with coronary artery disease7, 8 and in 
tubular compartments of patients with diabetic nephropathy.9 In Zucker diabetic fatty (ZDF) 
rats, decreased aortic vasodilatation was accompanied by an increase in senescent positive 
endothelial cells in the aorta.10 The ZDF rat develops obesity-related diabetes associated 
with increased levels of free fatty acids and ROS in its vasculature.11, 12 Treatment of these 
animals with the anti-oxidant drug ebselen prevented vascular senescence and reduced 
vasculopathy.10 
In the treatment of type 2 diabetes, the glucagon-like peptide 1 (GLP-1) receptor is a 
novel target. GLP-1 is proglucagon-derived hormone produced by the intestinal L-cells in 
response to food intake and has a profound effect on glycemic control.13 GLP-1 reduces gastric 
emptying, and reduces glucagon secretion from the α-cells. Most pronounced are its effects 
on the β-cells where GLP-1 stimulates insulin production, increases proliferation and can 
reduce β-cell apoptosis.14  In vivo, active GLP-1 is rapidly degraded by dipeptidyl-peptidase 4 
(DPP-4). Therefore, more stable GLP-1 analogues, such as exenatide, and DPP-4 inhibitors, 
such as vildagliptin, have been developed for the treatment of type 2 diabetes. 
GLP-1 acts through the GLP-1 receptor, a G-coupled-protein receptor, which is 
abundantly present in the gastrointestinal tract, but has also been detected at lower levels in 
the nervous system, the heart, vascular smooth muscle and endothelial cells.15-17 GLP-1 is 
a potent vasodilator and is associated with the improvement of endothelial function in 
animal models and in type 2 diabetic patients.17, 18 Activation of the GLP-1 receptor can 
trigger at least 2 downstream pathways, generation of the second messenger cyclic adenosine 
monophosphate (cAMP) followed by activation of protein kinase A (PKA), and the indirect 
activation of epidermal growth factor receptor (EGFR) followed by phosphoinositide 
3-kinase (PI3K) and Akt signaling.14, 19
We hypothesized that GLP-1 receptor activation could be involved in reducing the 
detrimental effects of oxidative stress and reduce cellular stress in the vasculature. Here we 





All animal studies were conducted in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals and approved by the Committee for Animal Experiments 
of the University of Groningen. Male ZDF (ZDF-Leprfa/Crl) rats and lean littermate 
(ZDF-Leprfa/+/Crl) rats were obtained from Charles River (Charles River, Maastricht, 
the Netherlands). At 10 weeks of age, ZDF animals were allocated in two groups (n=7 
per group), and 1 group was treated with vildagliptin (Galvus®, Novartis Pharma AG, 
Basel, Switzerland) for 15 weeks at a dose of 3 mg/kg per day (via the drinking water). 
Untreated ZDF rats and age-matched lean controls (n=7) rats served as controls. 
Senescence-associated ß-galactosidase staining
Senescence was determined by senescence-associated β-galactosidase (sa-β-galactosi-
dase) staining.20
Senescence staining of aorta
Rat abdominal aorta was cleaned by removing fat and connective tissue and subsequently 
stained for senescence as described above. After staining, a part of the aorta was transversely 
cut and stored for cryo-sectioning, the rest of the aorta was cut longitudinally and pictures 
were taken from the aorta with a DSLR camera equipped with a 50 mm macro lens. Photos 
of aortas were randomized and the percentage of senescence staining was determined with 
ImageJ software.21
Cell culture
Primary human umbilical vein endothelial cells (HUVECs) were obtained from the 
Endothelial Cell Facility (University Medical Center Groningen, the Netherlands). HUVECs 
were isolated from 2 umbilical cords and prepared as previously described.22 Cells were 
cultured on 1% precoated gelatin plates at 37°C under 5% CO
2
. RPMI 1640 medium was 
supplemented with 20% FCS, 2 mmol/L 
L
-Glutamine, 5 U/mL heparin, 100 IU/mL penicillin, 
100 µg/mL streptomycin and 50 µg/mL endothelial cell growth factor extracted from bovine 
brain. Experiments were conducted with cell passage numbers between 2 and 6.
Premature senescence assay
Senescence was induced by adapting our previously published endothelial senescence 
model.5 In short, HUVECs were seeded at 5000 cells/cm2 on 1% gelatin-coated plates. 
After 24 hours medium was replaced with low-serum medium (2% fetal calf serum), 
followed by overnight incubation. Senescence was induced by exposing cells to 30 µmol/L 
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. After 1 hour medium was replaced with normal growth medium, and at confluence, 
the percentage of senescent cells was determined. Various concentrations of GLP-1, 
exendin-4, 8-Bromoadenosine-cAMP (8-Br-cAMP), and forskolin were administered 




 exposure, and exendin (9-39), LY294002, H89, KT 5720, and 
NG-monomethyl-
L
-arginine (L-NMMA) were administered 30 minutes before GLP-1 
addition. Senescent staining was performed as described above. Light microscopic pictures 
were taken on an inverted microscope with a x10 objective, and the number of senescent 
cells and total cell number were counted per microscopic field. In each well, 4 random 
fields were evaluated. Data from multiple experiments were compared by calculating the 




 group was set to 1.00 in 
each separate experiment.
Protein analysis
For Western blot analysis of whole cell lysates, the following antibodies were used: anti-
phosphorylated Akt (Ser473), anti phosphorylated CREB (87G3), anti-caspase-3 (8g10) 
(Cell Signaling Technology, Danvers, Mass), and anti-GLP-1-receptor (H55) (Santa Cruz 
Biotechnology, Heidelberg, Germany). For loading control, membranes were re-probed 
with β-actin antibody (Sigma-Aldrich), α-tubulin (Sigma-Aldrich), or GAPDH antibody 
(Fitzgerald Industries International, Acton, Mass). Signals were detected by ECL and 
quantified by densitometry (Syngene, Cambridge, United Kingdom). 
Quantitative real-time polymerase chain reaction
Relative expression of HO-1 and NQO1 genes was determined by quantitative polymerase 
chain reaction (qPCR). Gene expression was determined by correcting samples for reference 
gene values (cyclophilin A), and values were expressed relative to the control group per 
experiment. 
Comet assay
DNA damage was determined by the comet single cell electrophoresis assay, as described 
by the manufacturer (Trevigen, Gaithersburg, Md). 
Statistics
Data represent mean values ±standard errors (SE). Comparisons between groups 
were done by 1-way ANOVA with post-hoc Dunett correction. Comparison of the 
sa-β-galactosidase areas in the abdominal aortas and qPCR expression was performed by 
Mann-Whitney U test.  A probability value of less than 0.05 was considered significant. 
 
Expanded methods can be found as supplemental material.
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Figure 1. DPP-4 activity and senescence in ZDF animals treated with vildagliptin. A. Abdominal 
aortas stained with sa-β-galactosidase. Photos are representative pictures for the different treatment 
groups. B. Percentage senescence visible in the aortas of lean, ZDF and ZDF + vildagliptin treated 
animals after sa-β-galactosidase staining. Data are expressed as mean ±SE, n=7. * P<0.05 compa-
red with the lean group. C. Examples of endothelial cells stained positive for sa-β-galactosidase in the 
aortas of ZDF animals. Arrows indicate positive endothelial cells. D. Relative DPP-4 activities in lean, 
ZDF and ZDF + vildagliptin treated rats. Data are expressed as mean ±SE. Data are from at least 4 
animals per group. * P<0.05 compared with the ZDF + vildagliptin group. E. GLP-1 plasma levels in 
lean, ZDF and ZDF + vildagliptin treated animals. Data are expressed as mean ±SE, n=7. * P<0.05 


























































DPP-4 inhibitor vildagliptin decreases vascular senescence in vivo
Here we investigated vascular senescence in normal “lean” animals as compared with 
ZDF diabetic rats. Senescence in abdominal aorta was determined with the well-established 
sa-β-galactosidase staining.20 As shown in Figure 1A, staining was most pronounced in the 
areas of aorta side branches, in concordance with the study of Brodsky et al.10 Determination 
of the amount of senescence per vessel showed a significant increase in 25-week-old ZDF 
animals as compared with control lean animals (Figure 1B), 4.7±1.1% versus 2.3±0.5%. 
Histological analysis of the stained vessels confirmed that parts of the endothelial cell layer 
were stained positive for sa-β-galactosidase (Figure 1C). Treatment of the ZDF animals with 
vildagliptin resulted in a significant reduction of DPP-4 activity (Figure 1D) and an almost 
6 fold increase of GLP-1 plasma levels (Figure 1E). No changes in plasma glucose and insulin 
levels were observed and body weights remained constant with this treatment protocol 
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Figure 2. GLP-1 treatment protects HUVECs from stress induced senescence. A. Representative 
images of HUVECs stained with sa-β-galactosidase, 3 days after treatment with GLP-1, H2O2, or both. 
B. Dose response effect of GLP-1 treatment 30 minutes before cells were exposed to 30 µmol/l H2O2. 
The number of senescent cells is expressed relative to the H2O2 30 µmol/l group. Data are expressed 
as mean ±SE. Data from control, 30 µmol/l H2O2 and GLP-1 10 nmol/l + 30 µmol/l H2O2 were 
obtained from 7 experiments; the other data points were repeated 5 times. Open bar represents the 
non-treated control group. *P < 0.05 compared with the H2O2 group.
A B
Control  30 µmol/L H2O2
10 nmol/L GLP-1
+ 30 µmol/L H2O2





























these animals, to levels almost comparable to those of lean rats (2.6±0.6% versus 2.3±0.5%) 
(Figure 1A and 1B). This suggests that increased GLP-1 levels by DPP-4 inhibition have 
a protective effect on the vasculature. 
GLP-1 treatment inhibits ROS induced premature senescence
To investigate the effects of GLP-1 on endothelial senescence, we switched to the well-
established HUVEC cell system, which is known to be sensitive to stress-induced cellular 
senescence. In HUVECs, cellular senescence was induced by oxidative stress via exposure to 




 (30 µmol/L), which did not induce apoptosis, as confirmed by the 
absence of caspase-3 cleavage under these conditions (Supplemental Figure I). This low dose, 
however, resulted in a significant 3.4-fold increase, (from 2.00±0.25% to 6.82±0.88%), in the 
number of senescent cells 3 days after exposure, as determined by sa-β-galactosidase staining 
(Figure 2A). Treatment of HUVECs with GLP-1 attenuated the increase of senescent cells in 
a dose responsive manner (Figure 2B), with a maximum of approximately 63% reduction 
of senescent positive cells compared with non-GLP-1 treated group at a concentration of 









0.37±0.03; control group 0.32±0.03). 
In parallel to the sa-β-galactosidase staining also DNA damage was also investigated 







significantly increased DNA damage by 1.6-fold relative to the control group (Figure 3B). 




exposure induced DNA damage only by 1.1 fold. Thus, GLP-1 




as determined by the percentage tail 
DNA in a comet assay. Together, these findings suggest that GLP-1 treatment can reduce ROS 
induced DNA damage and consequently attenuate the increase in senescent HUVECs.
The protective effect of GLP-1 is receptor mediated 
Western blot analysis of cell extracts showed GLP-1 receptor expression in HUVECs 
(Supplemental Figure II), which is in line with other studies showing endothelial expres-
sion. 15, 17 Next we used the GLP-1 analogue exendin-4 (an agonist of the GLP-1 receptor). 




induced senescence in HU-
VECs (Figure 4A). Co-treatment with exendin (9-39), another GLP-1 derived peptide that 





 induced cellular senescence (Figure 4B). These data provide evidence that 
the GLP-1 protective effect is GLP-1 receptor mediated. 
The PI3K/Akt survival pathway is not required for the GLP-1 protective effect 
In pancreatic β-cells23 and neuronal cells24 GLP-1 prevented apoptosis through the 
activation of PI3K and Akt. Although the amount of oxidative stress used in this study 
did not induce apoptosis in our HUVEC cell model, the PI3K/Akt signaling pathway is 
a general survival pathway, and we therefore tested whether this pathway could be involved 
Figure 3. DNA damage in HUVECs 
measured by a comet assay, 24 hours 
after treatment. A. Panel of three 
examples of HUVEC DNA single-cell 
electrophoresis. Left, control; middle, 
1 hour 30 µmol/l H2O2 exposure; 
right, treated with 10 nmol/l GLP-1 
for 30 minutes followed by H2O2 
exposure. B. Ratio of tail DNA in the 
different treatment groups. Ratios are 
expressed relative to the non-treated 
control group (open bar). Data are 
expressed as mean ±SE. Data are from 
3 different experiments. *P < 0.05 






























Control30 µmol/L H2O2 10 nmol/L GLP-1 +
30 µmol/L H2O2
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in the protective effect of GLP-1. The activity of Akt kinase was determined using an 
antibody against phosphorylated serine 473, the activation residue of Akt. Western blot 
analysis with this antibody did not reveal any change in Akt activity between control and 




 (Figure 5A and 5B), indicating that GLP-1 
does not activate this kinase under these conditions in HUVECs. To further rule out the 
involvement of this pathway, the upstream activator of Akt, PI3K, was inhibited using the 
small molecule LY294002 (Supplemental Figure III). As shown in Figure 5C, inhibition of 
PI3K by LY294002 did not result in a decrease of the protective effect of GLP-1 in HUVECs. 
Together these data do not support a role of the PI3K/Akt pathway in the GLP-1 mediated 
effect in HUVECs. 
GLP-1 protective effect is cAMP/PKA dependent 
The GLP-1 receptor is a G-protein coupled receptor and activates adenylate cyclase, 
resulting in cAMP production and downstream PKA activation. We therefore investigated the 
involvement of this intracellular signaling cascade in the GLP-1 protective effect. Treatment 




-induced cellular senescence in 
HUVECs (Figure 6A). Similar results were obtained with 8-Br-cAMP, a membrane permeable 
cAMP analogue (Supplemental Figure IV A). The effect of forskolin was dependent on the 
downstream cAMP effector PKA, as specific inhibition of PKA with H89 could abolish 
the forskolin-mediated protection. PKA inhibition by H89 was also sufficient to block the 
GLP-1 mediated protective effect on HUVECs (Figure 6B). H89 inhibition showed a dose 
Figure 4. Effects of exendin-4 and exendin-fragment 9-39 on cellular senescence. Senescence is 
expressed relatively to the H2O2 group. A. Effect of the GLP-1 receptor analogue exendin-4 on cellular 
senescence. B. Effect of the GLP-1 receptor antagonist exendin (9-39). For both graphs senescence 
is expressed as the relative ratio to the H2O2 groups. Data are expressed as mean ±SE. Data were 
obtained from 4 experiments; the controls exendin-4 10 nmol/l and exendin fragment (9-39) + GLP-1 


































































response effect on the cellular senescence in combination with GLP-1, with a complete 
abolishment of the GLP-1 protective effect at a concentration of 1 µmol/L H89 (Figure 6B). 
Similar results were obtained with another PKA inhibitor KT 5720 (Supplemental Figure 
IV B). These results indicate that PKA activation by GLP-1 is sufficient to prevent cellular 
senescence in HUVECs under these conditions.
GLP-1 activates CREB and induces expression of HO-1 and NQO1
A downstream target of PKA is the transcription factor CREB, which is activated by PKA 
phosphorylation and regulates expression of numerous genes in conjunction with other 
transcription factors. Western blot analysis using an anti phosphorylated CREB antibody 
showed that GLP-1 treatment increased relative phosphorylated CREB levels by 52% as 
compared with the control (Figure 6C and 6D). This effect was abolished by PKA inhibition 
using H89 (Figure 6C-D). Similar results were obtained with forskolin (Figure 6C and 6D). 
Quantitative PCR analysis of heme-oxygenase 1 (HO-1), a reported anti-oxidative target 
Figure 5. Effect of GLP-1 on Akt and PI3K inhibition. A. Representative blot showing phosphorylated 
Akt (Ser473) and β-actin levels from the following treatment groups: 1 = control, 2 = 30 µmol/l 
H2O2, 3 = 10 nmol/l GLP-1 + 30 µmol/l H2O2, 4 = 10 nmol/l GLP-1, PC = positive control (30 
minutes medium with 20% FCS and growth factors), and m = molecular marker lane. Cell extracts 
were prepared after 1 hour H2O2 exposure. B. Relative levels of phosphorylated Akt, after GLP-1 or 
H2O2 treatment or a combination of the two. Data from 3 experiments. C. Effect of the PI3K inhibitor 
LY294002 on the protective effect of GLP-1. Data were obtained from 4 experiments. Open bar 
represents the non-treated control group. *P < 0.05 compared with H2O2 groups.
A
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gene of CREB25, showed a concomitant induction after GLP-1 treatment. Also, another anti-
oxidative gene, NQO1 (NAD(P)H dehydrogenase quinone 1), was significantly induced by 
GLP-1 (Figure 6E and 6F). These data show that GLP-1 can activate the transcription factor 

























































































































































Figure 6. GLP-1 mediated protection is PKA dependent and involves CREB phosphorylation and 
induction of anti-oxidant genes. A. Effect of forskolin on cellular senescence with or without the PKA 
inhibitor H89. Open bar represent non-treated control group. Data are expressed as mean ±SE and 
were obtained from 4 experiments. *P < 0.05 compared to H2O2 group. B. Effect of the PKA specific 
inhibitor H89 on GLP-1 mediated cellular protection. Open bar represents the non-treated control 
group. Data are expressed as mean ±SE and were obtained from 4 experiments; H89 0.01 µmol/l 
+ 10 nmol/l GLP-1 was repeated 3 times. *P < 0.05 compared with H2O2 group. C. Representative 
blot of phosphorylated CREB protein of HUVEC samples treated with forskolin, GLP-1 or GLP-1 
in combination with H89. α-tubulin was used as loading control. D. Quantification of the relative 
phosphorylated CREB levels. Phosphorylated CREB levels were corrected for the loading control, 
α-tubulin, and results are from three different experiments (n=3). The control goup was set at one. 
Open bar represents the non-treated control group. *P < 0.05 compared with the control group. 
E and F. Relative expression of HO-1 (E) and NQO1 (F) mRNA levels in HUVECs after GLP-1 
treatment. Gene expression is relative to non-treated control samples (n=6), which were set to 1.0. 




GLP-1 analogues and DPP-4 inhibitors are novel therapeutic agents for the treatment 
of diabetes mellitus. These drugs are primarily designed to improve glycemic control. 
Interestingly, evidence is accumulating that GLP-1 and its analogues can also protect 
cardiovascular damage via ancillary pathways.15, 26 In particular, GLP-1 has been shown 
to induce vasodilatation and improve endothelial function.17, 18 In the present study, we 
showed that GLP-1 can protect endothelial cells against oxidative stress induced cellular 
senescence. 
In ZDF diabetic rats, increased levels of vascular senescence were observed, which is in 
agreement with a previous study.10 Treatment with the DPP-4 inhibitor vildagliptin raised 
GLP-1 levels and attenuated vascular cell senescence in these animals, almost to lean animal 
levels. Although DPP-4 inhibitors are used to improve glycemic control in diabetic patients, 
several studies have reported limited effects in glycemic parameters with these overtly 
diabetic ZDF rats upon DPP-4 inhibition or treatment with GLP-1 analogues.27-29 In line 
with this, analysis of blood glucose and insulin levels at the end of our experiment showed 
only slight, but not significant, changes in the vildagliptin treated animals as compared 
with the nontreated ZDF animals. However, we did not perform intermediate analysis or 
glucose tolerance tests and therefore cannot exclude possible changes in glucose handling 
in these animals upon treatment. Irrespective of this, our results show that DPP-4 inhibition 
can attenuate vascular senescence in vivo, most likely via GLP-1.
Our in vitro model system with primary HUVECs supported the observation that 
GLP-1 could directly attenuate endothelial senescence and provided molecular details. First, 
we observed that GLP-1 treatment had a protective effect on ROS-induced senescence in 
HUVECs. Second, this was associated with a reduction in DNA damage, further supporting 
a protective effect of GLP-1. We cannot rigorously exclude that in vivo also other potential 
DPP-4 targets might have exerted some effects on the vasculature. We note, however, that the 
only other established clinically relevant DPP-4 substrate is glucose-dependent insulinotropic 
polypeptide (GIP)30, but the receptor of this hormone is strongly downregulated in 
hyperglycemic ZDF rats.31 Therefore, we strongly believe that the observed in vivo effects 
must be GLP-1 mediated.
It has been shown in pancreatic β-cells that GLP-1 reduced apoptosis, stimulated survival 
and proliferation, and increased insulin secretion. These effects of GLP-1 have primarily 
been ascribed to the activation of downstream cAMP/PKA and PI3K/Akt signaling pathways 
in these cells.23, 32, 33 Also, the cardioprotective effect of GLP-1 after ischemia/reperfusion 
could be abolished by inhibiting cAMP, and PI3K34, indicating that the protective effects 
of GLP-1 generally involves multiple pathways. Our data indicate that in endothelial cells 
PI3K/Akt signaling is not activated by GLP-1 and accordingly, inhibition of this pathway 
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could not abolish the GLP-1 protective effect. The cAMP/PKA pathway, on the other hand, 
was clearly required for the GLP-1 protective effect in endothelial cells. Thus, it appears 
that in different cell types, different pathways are involved in GLP-1 pro-survival or anti-
senescence mechanisms. Because the GLP-1 receptor directly activates adenylate cyclase 
via Gαs,35 it is not surprising that the cAMP/PKA pathway is generally involved in this 
mechanism. PI3K activation by GLP-1 is indirect, however, involving IRS2 expression or 
EGFR transactivation36, and this latter mechanism is apparently not active in endothelial 
cells. 
We also showed here that GLP-1 could induce phosphorylation of the transcription 
factor CREB, in a PKA-dependent way, in endothelial cells. CREB phosphorylation results 
in its activation, and previous studies have shown that CREB phosphorylation is associated 
with cellular survival in pancreatic β-cells.33, 37 CREB binding site profiling studies have 
predicted at least 4000 putative target genes, but probably only a few percent are controlled 
by cAMP, and specific target genes are difficult to define.38 We investigated the expression 
of the oxidative stress defense gene HO-1, which is at least partially regulated by CREB.25 
We could show here that HO-1 expression in endothelial cells was significantly induced by 
GLP-1. This extends a previous observation in which in vivo liraglutide treatment resulted 
in HO-1 induction and cytoprotection of cardiac tissue.39 Another oxidative defense gene, 
NQO1, a potential downstream target of the GLP-1 induced the Nrf2/CREB binding protein 
pathway39, was also induced in endothelial cells in our study. These results indicate that 
GLP-1 can activate oxidative stress defensive pathways in endothelial cells. 
Recently, it was also shown that GLP-1 can reduce the inflammatory response of 
endothelial cells upon exposure to advanced glycation end product (AGE).40 Because 
AGE formation correlates with ageing and cellular senescence this could be a second path 
by which GLP-1 protects endothelial cells. Interestingly, the authors showed that GLP-1 
attenuated the expression of the AGE receptor RAGE, and this was mimicked by 8-Br-cAMP, 
indicating involvement of PKA signaling. This suggests that GLP-1 might activate multiple 
cytoprotective mechanisms and could have wide-ranging cytoprotective effects in cells. 
Expression profiling and proteomics approaches would be required to further map these 
global protective changes exerted by GLP-1.
Our data on endothelial senescence provided clear evidence that the GLP-1 protective 
effect in this setting was conferred by the GLP-1 receptor. HUVECs express the GLP-1 
receptor and both exendin-4 and GLP-1 provided protective effects, which were abolished 
by the antagonist exendin (9-39). To our knowledge this is the first study that links 
activation of the GLP-1 receptor to a protective effect on cellular senescence. In a recent 
report, GLP-1 receptor dependent anti-apoptotic effects were described for exendin-4 
in mouse cardiomyocytes41, which is in line with our observed anti-senescence effects 
in endothelial cells. Surprisingly, however, they did not observe this effect in endothelial 
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(700 µmol/L). Thus, 
GLP-1 and exendin-4 can apparently prevent endothelial senescence and cardiomyocyte 
apoptosis, but not apoptosis in endothelial cells. Interestingly, Ban et al41 did observe anti-
apoptotic effects in cardiomyocytes and endothelial cells with the “inactive” cleaved form 
of GLP-1, GLP-1(9-36), in a GLP-1 receptor independent manner. Whether this form 
has anti-apoptotic or anti-senescence activity on endothelial cells in vivo is, however, not 
known. Because DPP-4 inhibition only increases the levels of uncleaved GLP-1(7-36), 
as performed in this study, we have at this stage only evidence that uncleaved GLP-1 can 
attenuate endothelial senescence. 
In aging and in replicative senescence, NO levels tend to deteriorate42, and NO is an 
important factor in preventing or delaying the onset of endothelial senescence.43, 44 We 
therefore also considered the role of NO. We could not, however, abrogate the GLP-1 induced 
protection (Supplemental Figure V), by L-NMMA, a NO synthase inhibitor, indicating that 
NO was not involved. Interestingly, in endothelial cells anti-apoptotic effects by the cleaved 
GLP-1(9-36) form did appear to be NO mediated, indicating that this follows a different 
route, as compared with the anti-senescence effects of GLP-1.41
In conclusion, we have shown that GLP-1 has a protective effect on endothelial cells 
via GLP-1 receptor-mediated cAMP-dependent activation of PKA. The latter was both 
sufficient and essential for the GLP-1 induced effect. This GLP-1 effect on endothelial cells 
was independent of the PI3K/Akt survival pathway and did not require NO synthesis. 
These findings provide further evidence for the potentially extraglycemic, pleiotropic, effects 
of GLP-1 and DPP-4 inhibitors and could serve as a starting point to further investigate the 
protective mechanisms and to explore GLP-1 treatment options to delay disease and aging 
related endothelial senescence.
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GLP-1 (7-37) (GLP-1), 8-Bromoadenosine 3′,5′-cyclic monophosphate sodium 
salt (8-Br-cAMP), NG-Methyl-L-arginine acetate salt (L-NMMA), H-89 dihydrochloride 
hydrate (H89), forskolin, LY-294,002 hydrochloride (LY294002), bradykinin, exendin-4, 
exendin fragment 9-39 (exendin (9-39)), and KT 5720 were all obtained from Sigma-
Aldrich (Zwijndrecht, The Netherlands). The Accu-Check Aviva kit (Roche, Almere, The 
Netherlands) was used to determine blood glucose levels at sacrifice. Serum DPP-IV activity 
(Quantizume Assay System, BIOMOL International, Plymouth Meeting, PA, USA), active 
GLP-1 (Glucagon-Like Peptide-1 (Active) ELISA Kit (Millipore Corporation, Billerica, MA, 
USA)) and insulin levels (enzymatic assay ALPCO Diagnostics, (Rat) EIA, ALPCO Diagnostics, 
Salem, NH, USA) were all determined using commercially available kits, according to the 
manufacturer instructions.
Senescence associated β-galactosidase staining
Cells or tissue were washed in PBS and fixed in 2% formaldehyde and 0.2% glutaraldehyde 
for 10 minutes. Subsequently, cells or tissue were washed and incubated for 18 hours at 37°C 
with sa-β-galactosidase staining solution (150 mmol/l NaCl, 2 mmol/l MgCl
2









), 40 mmol/l citric acid / sodium phosphate dibasic at pH 
6.0, containing 1 mg/mL X-gal (5-bromo-4-chloro-3-indolyl-D-galactoside)).  
Comet Assay
HUVEC cells were treated as described above and 24 hours after treatment cells were 
harvested and approximately 700 cells were placed on a CometSlide in LMAgarose (Trevigen, 
Gaithersburg, MD, USA). Cells were lysed for one hour at 4°C in Lysis Solution, followed 
by denaturation for 30 minutes in 300 mmol/l alkaline solution, 1 mmol/l EDTA pH>13. 
Electrophoresis was done in an alkaline electrophoresis solution (200 mmol/l NaOH 
1 mmol/l EDTA pH>13). Comet slides were stained with SYBR Green and photos were 
taken with a 20x objective. Pictures were analyzed with CASP 1.2.2 software.1  Experiments 
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Quantitative Real-Time PCR
Total RNA was isolated from cells by Nucleospin II kit (Machery-Nagel, Düren, 
Germany) and converted to cDNA by QuantiTect Reverse Transcription (Qiagen, Venlo, The 
Netherlands).
Gene expression was measured with ABsolute QPCR SYBR Green ROX Mix (Abgene, 
Epsom, United Kingdom) in the presence of 5 ng cDNA and 200 nmol/l forward and 
reverse primers. Real-Time PCR was conducted on the Biorad CFX384 (Biorad, Veenendaal, 
The Netherlands) Primers used: HO-1 forward CAACAAAGTGCAAGATTCT, HO-1 reverse 
TGAGTGTAAGGACCCATC, NQO1 forward AACTTCAATCCCATCATTT, NQO1 reverse 
TATAAGCCAGAACAGACT, cyclophilin A forward ACTTCACACGCCATAATG, cyclophilin A 
reverse ACCCGTATGCTTTAGGAT.
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Supplemental table I. Characteristics of lean, ZDF and ZDF + vildagliptin groups at sacrifice.
Rats were 25 weeks of age. 
lean ZDF ZDF + vildagliptin
Number of animals 7 7 7
Body weight (g) 387 ±11 410 ±19 409 ±8
Plasma glucose (mmol/l) 9.6 ±0.4 23.9 ±1.7* 21.5 ±2.4*
Plasma insulin (ng/10µl) 0.28 ±0.04 0.28 ±0.05 0.34 ±0.04
Data presented as means ± SE *P < 0.05 versus lean.
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Supplemental Figure I 
Supplemental Figure I. Caspase-3 cleavage in HUVEC cells treated with 10 nmol/l GLP-1
followed by 1 hour exposure to 30 µmol/l H2O2. Caspase-3 cleavage was measured immediately
after H2O2 (1 hour) or 24 hours after H2O2 exposure. C = control group, H = H2O2 30 µmol/l group,
H+G = GLP-1 10 nmol/l + H2O2 30 µmol/l group and G = GLP-1 10 nmol/l group. Positive control
(PC) sample is HUVEC cells treated for 24h with 0.5 µmol/l staurosporine. Beta-actin levels 
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Supplemental Figure I. Caspase-3 cleavage in HUVEC cells treated with 10 nmol/l GLP-1 followed 
by 1 hour exposure to 30 µmol/l H 2O2. Caspase-3 cleavage was measured immediatelyafter H 2O2 
(1 hour) or 24 hours after H 2O2 exposure. C = control group, H = H2O2 30 µmol/l group,H+G = GLP-1
10 nmol/l + H 2O2 30 µmol/l group and G = GLP-1 10 nmol/l group. Positive control (PC) sample 
is HUVEC cells treated for 24h with 0.5 µmol/l staurosporine. Beta-actin levels detected on the same 







Supplemental Figure II. Detection of the GLP-1 receptor in HUVEC cell extracts.
Membrane shows GLP-1 receptor band at 56 kDa, GAPDH (37 kDA) level detected
on the same membrane is shown as loading control. 
Supplemental Figure II. Detection of the GLP-1 receptor in HUVEC cell extracts. Membrane shows 
GLP-1 receptor band t 56 kDa, GAPDH (37 kDA) level detectedon the same membrane is shown as 
loading control.
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Supplemental Figure III. LY294002 inhibits phoshorylation of Akt in HUVEC cells. 
Lane 1: Non-treated control. Lane 2: 30 minutes of LY294002 1 µmol/l treatment. 
Lane 3: 30 minutes 20% FCS. Lane 4: 30 minutes of 1 µmol/l LY294002 followed 
by 30 minutes of 20% FCS treatment. Bands represent phoshorylated Akt (60 kDa)
and GAPDH levels (37 kDa) on the same membrane as loading control.
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Supplemental Figure III. LY294002 inhibits phoshorylation of Akt in HUVEC cells. Lane 1: Non-
treated control. Lane 2: 30 minutes of LY294002 1 µmol/l treatment. Lane 3: 30 minutes 20% FCS. 
Lane 4: 30 minutes of 1 µmol/l LY294002 followed by 30 minutes of 20% FCS treatment. Bands 





Supplemental Figure IV. A. Effect of 8-Br-cAMP on H2O2 induced senescence. Data were 
obtained from 6 experiments. B. Effect of the PKA inhibitor KT 5720 on GLP-1 mediated 
protective effect. Data from 4 experiments. For both graphs, data are expressed as means

































































Supplemental Figure IV. A. Effect of 8-Br-cAMP on H 2O2 induced senescence. Data were obtained 
from 6 experiments. B. Effect of the PKA inhibitor KT 5720 on GLP-1 mediated protective effect. Data 
from 4 experiments. For both graphs, data are expressed as means ± SE, open bars represents non-
treated control groups, *P < 0.05 compared to H 2O2 group.
109
GLP-1 prevents endothelial cell senescence
5
Supplemental Figure V. Effect of NO inhibition on GLP-1 mediated cellular protection. 
The effect of L-NMMA inhibition on the protective effect of GLP-1. Data are expressed as means ± SE. 
Data obtained from 5 experiments. Open bar represents non-treated control group. *P < 0.05 compared 
to H 2O2 group.
Supple ental Figure V. Effect of NO inhibition on GLP-1 mediated cellular protection. 
The effect of L-NMMA inhibition on the protective effect of GLP-1. Data are expressed
as means ± SE. Data obtained from 5 experiments. Open bar represents non-treated













































Summary and discussion 
As we progress to a society with an increasing average age, the problems that are associated 
with advanced age become more prominent. Aging is characterized by a slow regression 
of functionality of tissues and organs to a point that essential functions ultimately fail. The 
process of aging is often accompanied by the onset of aging-associated diseases. Examples 
of such diseases are cardiovascular disease, diabetes or cancer that in turn substantially 
progress the age-related functional deterioration of tissues. On a cellular level, aging is 
characterized by an accumulation of damage that eventually changes a cell to the extent that 
it is less capable of performing its primary functions or even looses its function completely. 
In cell culture, cellular aging is characterized by growth arrest that is accompanied by 
a prominent phenotype, which is termed cellular senescence. Primary cells that reach this 
“aging” state attain a growth arrest, but they do not disappear from the culture, in contrast 
to processes like apoptosis or necrosis.1, 2 Cellular senescence can occur after cells have 
reached their maximal replicative potential, also known as the Hayflick limit. However, 
cellular senescence can also occur before the Hayflick limit is reached due to sub-lethal 
doses of stress. In senescence research, a distinction is made between the replicative form 
and the stress-induced form of senescence, and these different causes for senescence may 
well be amenable to differential therapy. How cells become senescent and the implication 
of senescent cells in aging tissue have been discussed in chapter 1 of this thesis. 
Replicative senescence is associated with telomere shortening. Telomeres consist 
of repetitive sequences at the chromosome ends and prevent DNA damage checkpoint 
activation and unwanted recombination.3 Progressive telomere shortening due to the end-
replication problem or DNA damage results in telomere instability, which eventually can 
induce senescence.4 Telomerase is the responsible enzyme for telomere elongation, and is 
primarily active in dividing cells as well as germline cells, stem cells, and haematopoietic 
precursor cells.5 Telomerase activity is low in somatic cells6, but is active in more than 90% 
of all tumors. Therefore, it has been suggested that increased telomerase activity is required 
for tumor formation, to overcome cellular senescence.7 The importance of telomerase 
activity became clearly evident in telomerase knockout mice, in which telomere length 
shorten with each generation, accompanied by a premature aging phenotype.8, 9 In chapters 
2 and 3 of this thesis we focused on telomere and telomerase biology. The detrimental 
effects of telomere shortening on aging, and on aging associated diseases were discussed in 
chapter 2. In chapter 3 we investigated the effects of voluntary exercise on cardiovascular 
function in telomerase deficient mice. Exercise is associated with an upregulation of 
telomerase10, 11 and is associated with preventing telomere shortening and the effects 
of aging.12  Telomerase knockout mice lack the gene encoding the RNA component (TERC) of 
the enzyme telomerase. The most striking observation was the reduced exercise performance 
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of the TERC-/- mice in comparison to wild-type (WT) mice. Running wheel performance 
of TERC-/- generation 3 (G3) mice was less than TERC-/- G2. Telomere length, as expected, 
was shorter in TERC-/- mice, and G3 had shorter telomeres than G2 mice. Our results were 
different from results with exercise research in TERT knockout mice. These animals lack the 
catalytic subunit of telomerase and did not show a difference in exercise performance.10, 11 
The difference in exercise performance was not associated with a strong cardiovascular 
phenotype in the TERC-/- mice. There was a difference in the maximal vasodilatation of the 
aorta of the animals. Exercise improved maximal vasodilatation in WT animals, but not in 
the TERC-/- animals. Strikingly, in a study with aged mice, older animals also performed 
less in a voluntary wheel running model in comparison to young animals, but exercise 
improved endothelial function of all animals.13 Also TERT-/- mice improved endothelial 
vasodilatation after voluntary exercise.10 The differences in exercise performance between 
the TERC-/- and TERT-/- mice are remarkable and at the moment unexplained. Further 
research into telomerase knockout models might elucidate the fundamental difference in 
relation to exercise, and might thereby improve our understanding of the relation between 
telomere length and exercise performance.
In the second part of this thesis we changed from replicative senescence to stress-induced 
forms of senescence. In particular we studied the effects of stress on endothelial cells. Stress, 
predominantly oxidative stress, increases with age and the resulting accumulation of damage 
is an important contributor to aging. For vascular disease, aging is one of the major risk 
factors14, and the presence of senescent cells in atherosclerotic plaques are thought to play 
an important role in atherogenesis.15 We focused on endothelial cells, as the endothelium 
is located at the barrier between blood and the underlying tissue, and the endothelium has 
therefore, a relatively high exposure to physiological and oxidative stress. Endothelial cell 
senescence is thought to be an important contributor to vascular aging and is suggested to 
negatively influence endothelial function and might therefore be an important contributor 
to the onset and progression of endothelial dysfunction.16, 17 As endothelial dysfunction 
is present in multiple cardiovascular and other aging associated diseases, improvement of 
the endothelial function could potentially be an important contributor in ameliorating the 
detrimental effects of cardiovascular aging.15, 18 We wondered whether it would be possible 
to prevent endothelial senescence, and if so, what are the mechanisms involved. 
During aging, nitric oxide (NO) levels decrease in endothelial cells and restoring 
the NO bioavailability could be an interesting option to improve endothelial function.19 
A potent NO stimulatory hormone is bradykinin, and its receptor density decreases 
with age.20 We therefore tested the effect of bradykinin on endothelial senescence. In 





senescence in an in vitro model with bovine aortic endothelial cells (BAECs). Senescence was 
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. Pharmacological inhibitor studies showed 
that bradykinin prevented senescence through the G-protein coupled receptor bradykinin 
2 receptor (BK2-R). The BK2-R receptor is constitutionally expressed, in contrast to the 
BK1-R that is only expressed during tissue activation, for instance during inflammation. 
In our in vitro model the protective effect of bradykinin was mediated through the BK2-R, 
although this does not exclude the BK1-R as a potential contributor to protective effects 




 resulted in an increase in DNA damage, which would 
suggest that senescence was induced by the p53/p21 pathway. Protein analysis indicated 




exposure, while bradykinin treated cells had 
p21 protein levels that were comparable to non-treated cells. Further analysis indicated that 
blocking NO generation could totally abolish the bradykinin mediated effect. How NO 
prevents senescence is still unknown, some studies implicate that NO might upregulate 
telomerase19, 22, although the role of telomerase in response to NO is contradicted in another 
study.23 NO is a key regulator of endothelial function, and is associated with vasodilatation, 
inhibition of platelet aggregation, and reducing the upregulation of pro-inflammatory 
genes. In addition NO can also upregulate genes that are associated with anti-oxidative 
genes.24, 25 Later in this discussion we will focus more on the notion that the activation of 
anti-oxidative response pathways could be important for the protective effect of NO.
From this point forward, we focused on another hormone in relation to preventing stress 
induced senescence. Oxidative stress and a decline in endothelial functions are important 
in the progression of diabetes mellitus.26 A new class of anti-diabetic drugs have the aim 
to increase the levels of the hormone glucagon-like peptide 1 (GLP-1).27 This results in 
improving glycemic control and in addition reduces pancreatic β-cell apoptosis.28 A safe 
and relatively easy approach to increase GLP-1 levels is decreasing the levels of dipeptidyl 
peptidase-4 (DPP-4), which cleaves active GLP-1 resulting in its inactivation.29 Interestingly, 
increasing levels of plasma GLP-1 are also associated with improved endothelial function, 
independent of the effects of GLP-1 on glycemic control.30 We therefore focused on the 
effects of GLP-1 on endothelial senescence. Using an in vivo diabetic animal model, with 
increased endothelial senescence, DPP-4 inhibitor treatment resulted in a decrease of vascular 
senescence. The signaling pathways that are involved in the protective effect of GLP-1 were 
subsequently studied in an in vitro model with human umbilical vascular endothelial cells 
(HUVECs). GLP-1 mediated protection against oxidative stress induced senescence was 
mediated through the GLP-1 receptor and the subsequent activation of protein kinase 
A (PKA). Activated PKA on its turn upregulated CREB modulated transcription, thereby 
increasing the expression of protective genes like HO-1 and NQO1.
From part II of this thesis, we can conclude that it is possible to prevent endothelial 
senescence by two different pathways. (Figure 1) Bradykinin increases, through the activation 
of the G-protein coupled bradykinin B2 receptor, the bioavailability of NO. GLP-1 activates the 
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GLP-1 receptor, which is coupled to another G-protein and activates the transcription factor 
CREB, resulting in expression of a set of protective genes. It may be argued that both distinct 
pathways eventually result in the activation of overlapping protective genes or protective 
pathways. Although in our model the protective effect of GLP-1 was NO independent, a recent 
study indicates that the GLP-1 analogue, liraglutide, is anti-inflammatory by upregulating 
intracellular NO.31 Anti-oxidative stress related genes as, HO-1 and NQO1, are upregulated in 
response to oxidative stress.32 They are also upregulated in response to laminar flow (shear 
stress), and are associated with the protective effects of shear stress.33 In addition HO-1 and 
NQO1 have been described to be upregulated in response to increased levels of intracellular 
NO.24, 25 It seems therefore, that the activation of the bradykinin and GLP-1 receptors could 
result in an upregulation of similar pathways that are involved in the response to stress. So, 
the protective effect on a cellular level might be mediated by priming the cells for stress via 
activation of a similar stress response. Interestingly, this is also suggested for the beneficial 
effects of exercise. Physical activity increases physiological stress and oxidative stress and 
therefore activates stress response pathways that might be protective.34 In that respect, it is 
interesting to see that activation of stress pathways are also associated with the beneficial 
effects of caloric restriction. Reducing food intake lowers metabolism, which results in less 
oxidative stress, but also activates stress response pathways that might be beneficial.35 Overall 
this suggests that a limited amount of stress could be beneficial. 
Figure 1. Activation of 
two G-protein coupled 
receptors can induce 
two distinct pathways 




Our research into preventing endothelial senescence and the underlying mechanisms 
was for a large part performed in vitro. Therefore, further expansion into animal models 
and clinical testing will be necessary to test whether the suggested treatments could be 
beneficial in preventing cellular senescence and improve endothelial function. Our results 
with the use of the DPP-4 inhibitor, vildagliptin, in ZDF rats showed promising results 
in preventing senescence in vivo. These results have to be extended to other aging animal 
models, and it would be interesting to research these effects in humans. Interestingly, it has 
been demonstrated that GLP-1 can improve endothelial function in humans.30 Increasing 
NO bioavailability is potentially an important target to prevent endothelial senescence. The 
in vitro results obtained in chapter 4 show that senescence can be decreased by bradykinin, 
and is likely mediated by increasing NO bioavailability. Angiotensin-converting enzyme 
(ACE) inhibitors, which are aimed at reducing angiotensin II, also increase bradykinin 
levels. (Figure 1) ACE inhibitors would therefore, be a logical drug to target senescence. In 
addition, ACE inhibitors have a beneficial effect on endothelial function by improving intra-
cellular NO and eNOS signaling.36 Of importance for treating senescence by increasing 
intracellular NO, is to realize that NO is a reactive oxygen species, and therefore could also 
induce oxidation and cellular damage.37 In addition, if intra-cellular levels of NO become to 
high there is the risk of excessive vasodilatation, which could result in hypotension.38 
Future perspectives
ACE inhibitors, DPP-4 inhibitors, and also GLP-1 analogs, like liraglutide or exanatide, 
are used in a clinical setting, but so far there has been no research on the effects of these 
drugs on “aging” of cells in humans. Since these compounds are already investigated in 
a clinical setting it would be feasible to investigate the effects of these therapies on vascular 
senescence in humans. At the moment it is unknown how cells would react to combinational 
therapy, but this might be an interesting future challenge. 
Besides bradykinin and GLP-1, other signaling pathways that affect NO levels or 
activate CREB mediated transcription could be of interest in senescence research. A direct 
activation of CREB or administration of NO donors could even be a more direct approach 
to provoke protection. However direct upregulation of NO, which is an oxidative radical, 
can induce apoptosis39, and also the direct administration of different cAMP analogues, 
which upregulates CREB transcription, can potentially induce apoptosis.40 Most likely the 
over-activation of these pathways using these methods is detrimental. Therefore, although 
receptor mediated activation is more pleiotropic, it might be preferred because it gives 
a more physiological response.
In conclusion, the presence of senescent cells in aging tissue is evident41-43, but the exact 
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cause and underlying mechanisms are still unclear. The contribution of stress associated 
senescence to the aging phenotype is still not completely elucidated. The potential role as 
a tumor suppressor mechanism might be important against malignant cells.7 Another aspect 
might be that in certain cases senescence is preferential over the other forms of cellular 
decay, like apoptosis, since apoptotic cells disappear from the tissue. For the endothelium it 
is imaginable that senescence could be preferential over apoptosis. 
In cardiovascular diseases and diabetes mellitus, senescence most likely negatively 
influences the progression of the diseases. Especially, vascular tissue could be sensitive to 
the development of senescent cells, and be susceptible to the negative aspects of senescent 
cells.15  Therefore, preventing senescence could be a potential target to treat aging associated 
diseases, and targeting endothelial senescence would be an interesting first step. The 
availability of drugs that can potentially invoke a protective effect on senescence makes 
it attractive to further study anti-senescence in a clinical setting. Completely preventing 
aging is probably unlikely, as we cannot avoid cellular damage during life, but improving 
the response to stress might be within reach. At the moment the best described successful 
anti-aging therapy is caloric restriction, and although this is simple and very cheap, 
implementation in our society has proven to be very difficult, as most people are not 
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Onze samenleving wordt gemiddeld steeds ouder, daarmee worden we ook steeds meer 
geconfronteerd met de nadelige gevolgen van het ouder worden. In de gezondheidszorg is 
er een toename van ziekten die deels veroorzaakt worden door ouderdom. Voorbeelden van 
ouderdomsziekten zijn hart- en vaatziekten, diabetes mellitus type II en sommige vormen 
van kanker. Een belangrijk doel bij de behandeling van patiënten en een doel binnen het 
huidige medische onderzoek is er op gericht om de nadelige gevolgen van het ouder 
worden terug te dringen. 
Veroudering in organen wordt gekenmerkt door een geleidelijke afname van de 
functie totdat een orgaan niet meer kan functioneren. De effecten van veroudering zijn 
daarnaast ook zichtbaar op cellulair niveau. De meeste cellen in ons lichaam ondergaan zeer 
karakteristieke veranderingen op zowel morfologisch als op intracellulair niveau wanneer 
de cel ouder wordt. Dit verouderingsproces van cellen wordt in hoofdstuk 1 besproken. In 
dit hoofdstuk beschrijven we het ontstaan en de gevolgen van cellulaire veroudering, een 
proces dat ook wel cellulaire senescence wordt genoemd. 
Hoe senescence precies ontstaat, is nog niet duidelijk, maar een belangrijke rol is 
weggelegd voor eiwitten die betrokken zijn bij de celdeling, de transcriptie van genen 
en de inductie van geprogrammeerde celdood (apoptose). Hoewel de biologische functie 
van senescence nog niet bekend is, wordt het steeds duidelijker dat het aantal senescent 
cellen toeneemt naar mate we ouder worden en dat de aanwezigheid van senescent cellen 
in verschillende organen zoals in het vaatsysteem of in de nieren groter is bij patiënten 
die ouderdomsgerelateerde ziekten hebben. Eén van de hypotheses is dat senescence een 
anti-tumor mechanisme is, dat voorkomt dat een niet goed functionerende cel oneindig 
kan delen en een kankercel wordt. Dit houdt in dat senescence een intracellulair “failsafe” 
mechanisme is dat moet voorkomen dat beschadigde cellen zich kunnen verspreiden. Er 
zijn twee vormen van senescence. De eerste vorm is de replicatieve senescence waarbij 
een cel senescent wordt na een bepaald aantal delingen. Bij deze vorm van senescence 
spelen de uiteinden van de chromosomen (de telomeren) een belangrijke rol. De rol van 
de telomeren wordt besproken in de hoofdstukken 2 en 3. Daarnaast kan senescence ook 
geïnduceerd worden in cellen die nog niet hun maximale aantal delingen hebben gehaald, 
op het moment dat ze worden blootgesteld aan verschillende vormen van stress, zoals vrije 
zuurstof radicalen, radioactieve straling of UV straling. Deze tweede vorm van senescence 
wordt ook wel stress geïnduceerde senescence genoemd. In hoofdstuk 4 en 5 ligt de nadruk 
meer op deze vorm van senescence.
Bij het ontstaan van replicatieve senescence spelen de telomeren een belangrijke rol. In 
hoofdstuk 2 bespreken we de effecten van telomeerverkorting op het ontstaan van senescence 
en veroudering. De telomeren bevinden zich aan de uiteinden van de chromosomen, waar 
geen functionele genen aanwezig zijn en bestaan uit een opeenvolging van identieke stukjes 
DNA. Door de repeterende structuur kunnen de telomeren een cap structuur aannemen, die 
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ervoor zorgt dat het uiteinde van het chromosoom beschermd blijft. Bij te korte telomeren 
wordt deze cap niet meer gevormd en zullen de uiteinden van de chromosomen worden 
herkend als gebroken DNA, waardoor DNA-reparatie processen worden geïnitieerd, die 
uiteindelijk kunnen resulteren in senescence. 
Uit onderzoek is gebleken dat telomeren korter worden naarmate we ouder worden. 
De telomeerlengte kan echter sterk variëren tussen de verschillende chromosomen in een 
cel en metingen bij mensen hebben laten zien dat telomeerlengte tussen personen en 
bevolkingsgroepen eveneens sterk kan verschillen. Het is daardoor moeilijk om vast te stellen 
wanneer de telomeerlengte te kort is. Wel is gebleken dat de gemiddelde telomeerlengte 
van een persoon geassocieerd is met ouderdomsziekten. Telomeren worden korter doordat 
bij de celdeling de uiteinden van onze chromosomen niet volledig gerepliceerd kunnen 
worden. Daarnaast zijn telomeren gevoelig voor DNA schade, bijvoorbeeld door verhoogde 
niveaus van oxidatieve stress wat kan leiden tot telomeer instabiliteit en de inductie van 
senescence of apoptose. Om te voorkomen dat de telomeren te kort worden in stamcellen 
en cellen die verantwoordelijk zijn voor de voortplanting, hebben deze cellen een hoge 
activiteit van het enzym telomerase. Dit enzym is in staat is de telomeren te verlengen. De 
belangrijke rol die telomerase vervult, is zichtbaar in telomerase knock-out muizen. Deze 
dieren hebben door de afwezigheid van telomerase activiteit per generatie cumulatieve 
telomeerverkorting en een versneld verouderend fenotype, wat eveneens sterker wordt in 
de latere generaties dan in de eerste generatie van deze muizen.
Recent onderzoek heeft aangetoond dat er wellicht een link is tussen telomeerlengte 
en de gunstige effecten van regelmatige beweging. Daarom hebben we in hoofdstuk 3 
gekeken naar de effecten van vrijwillige beweging op telomerase knock-out muizen. Het 
belangrijkste resultaat in dit hoofdstuk was dat de telomerase knock-out muizen minder 
rennen ten opzichte van wild-type dieren. Hoewel we vergeleken met wild-type dieren 
kleine verschillen in de hart- en endotheelfunctie van de telomerase knock-out dieren 
zagen, konden deze verschillen niet de verschillen in prestatie in het loopwieltje verklaren. 
Waarschijnlijk zijn er meerdere kleine verschillen tussen telomerase knock-out en wild-
type dieren die het verschil in loopactiviteit veroorzaken, hoewel we op dit moment nog 
niet kunnen uitsluiten dat er andere grote afwijkingen zijn in organen waar we niet naar 
gekeken hebben. Daarom zou het interessant zijn om bij vervolg onderzoek ook goed te 
kijken naar metabolische en neurologische verschillen in combinatie met cardiovasculaire 
parameters.
In de eerste 3 hoofdstukken van dit proefschrift ligt de focus voornamelijk op het ontstaan 
van senescence en de rol van de telomeren en het enzym telomerase. In het tweede deel 
verschuift de focus naar stress geïnduceerde senescence in endotheel cellen en het gebruik 
van verschillende hormonen om senescence tegen te gaan. In hoofdstuk 4 beschrijven we 
in een celkweek model dat het hormoon bradykinine een beschermend effect heeft tegen 
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het ontstaan van senescence in endotheel cellen. Bradykinine is één van de stoffen die sterk 
verhoogd aanwezig is bij het gebruik van ACE inhibitors, medicijnen die de bloeddruk 
verlagen. In een model met bovine aortic endothelial cells (BAECs) hebben we laten zien dat 
een milde blootstelling aan oxidatieve stress resulteert in senescence, doordat de oxidatieve 
stress het DNA beschadigt. Het ontstaan van senescence na blootstelling aan oxidatieve stress 
is door middel van een specifieke kleuring zichtbaar gemaakt. Daarnaast werd senescence 
aangetoond door de upregulatie van het senescence eiwit p21. Bradykinine behandeling 
voorafgaand aan de blootstelling aan oxidatieve stress resulteerde in minder DNA schade, 
leidde tot een afname van de p21 eiwit levels en herstelde de migratie capaciteit van de 
cellen. Met inhibitor proeven hebben we vastgesteld dat het beschermende effect van 
bradykinine afhankelijk is van de bradykinine-2 receptor en stikstofmonoxide (NO), een 
essentiële signaalstof voor endotheelcellen met intracellulaire en extracellulaire functies. 
In hoofdstuk 5 laten we vervolgens zien dat vasculaire senescence ook via een andere 
moleculaire route kan worden voorkomen. Een relatief nieuw doel in de strijd tegen diabetes 
mellitus type II is het remmen van dipeptidylpeptidase 4 (DPP-4), door bijvoorbeeld het 
medicijn vildagliptin. Primair zijn DPP-4 inhibitors erop gericht de insulineafgifte te 
verhogen en glucagonconcentraties te verlagen in patiënten, door het verhogen van de 
plasmaconcentraties van het hormoon Glucagon Like Peptide 1 (GLP-1). Dit hormoon 
heeft naast het effect op het insuline- en glucagonmetabolisme ook een effect op de 
vaatfunctie. Een opvallend kenmerk van vaten uit diabetes type II patiënten of bij diabetes 
proefdiermodellen is de aanwezigheid van senescent cellen in de vaatwand. In hoofdstuk 5 
laten we in een proefdiermodel voor diabetes zien dat vildagliptin behandeling resulteert 
in een verminderde hoeveelheid senescence positieve cellen in de vaatwand. Om meer 
inzicht te krijgen in de onderliggende moleculaire routes hebben we de betrokken 
moleculaire routes onderzocht in een celkweekmodel met humane endotheelcellen. De 
cellen werden blootgesteld aan oxidatieve stress, wat resulteerde in stress-geïnduceerde 
senescence. Behandeling van de cellen met GLP-1 beschermde de cellen tegen stress 
geïnduceerde senescence. Door gebruik te maken van inhibitors konden we vaststellen dat 
het beschermende effect gemedieerd wordt door de GLP-1 receptor en dat deze receptor 
de second-messenger cyclisch adenosine monofosfaat (cAMP) activeert. Het beschermende 
effect is protein kinase A (PKA) afhankelijk en loopt via de activatie van de transcriptiefactor 
cAMP response element-binding (CREB). CREB is op zijn beurt in staat om beschermende 
genen tegen oxidatieve stress te activeren. Opvallend is dat dit beschermende effect 
van GLP-1 niet afhankelijk is van stikstofmonoxide, zoals het geval was in hoofdstuk 4. 
Uit hoofdstukken 4 en 5 kan geconcludeerd worden dat het mogelijk is om senescence te 
voorkomen en dat dit kan via de activatie van twee verschillende moleculaire pathways. 
In hoofdstuk 6 zijn de gevonden resultaten samengevat en besproken in relatie tot 
de verouderingsbiologie. Interessant is dat de moleculaire pathways die beschermende 
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effecten hebben ten opzichte van senescence eveneens een rol spelen bij de natuurlijke 
respons op stress. Voor toekomstig onderzoek is het daarom interessant om te kijken naar 
de verdere mogelijkheden om deze routes te gebruiken om ouderdomsziekten uit te stellen 
of tegen te gaan. Daarnaast is het interessant om te onderzoeken in hoeverre de routes nog 
intact zijn bij oudere patiënten, om een beter beeld te krijgen van de mogelijkheden om 
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Wiek, je steun en vertrouwen zijn een grote stimulans geweest. De ruimte die er was om 
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en hulp zijn onveranderd gebleven ondanks dat we niet meer in dezelfde groep werkten. 
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